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CHAPTER 1 
General Introduction 
Avian Influenza:  Avian influenza (AI) viruses are enveloped, segmented, negative-
sense RNA viruses belonging to the family Orthomyxoviridae genus influenzavirus A  (1, 2).  AI 
viruses have been isolated from over 100 species covering 12 orders of birds and naturally 
circulate in their primary natural reservoirs, wetland and aquatic birds, the Anseriformes (ducks, 
geese, and swans) and Charadriiformes (gulls, terns, and shorebirds) (1, 3-6).  Anseriformes and 
Charadriiformes are considered to be the primary natural reservoirs because AI viruses are 
reliably isolated from particular species in these orders of birds (7).  Influenza A viruses are 
classified by their two major antigenic determinants, the transmembrane glycoproteins 
hemagglutinin (HA) and neuraminidase (NA) (1).  With the exception of the recently isolated 
H17 from A/bat/Guatemala/09 all HA subtypes (H1-H16), all 9 subtypes of NA (N1-N9) and 
105 of the theoretical HA/NA virus combinations have been identified in Anseriformes and 
Charadriiformes (5, 8-11). 
Wild waterfowl live with AI viruses in evolutionary stasis with carriers typically 
remaining asymptomatic, indicating an ancient association and an optimal level of adaptation 
(12-14).  The vast majority of AI viruses are considered to be low pathogenic AI (LPAI) or 
mildly pathogenic AI (MPAI) viruses which produce either subclinical infections or mild 
respiratory and/or reproductive diseases (3, 15).  LPAI viruses replicate in the intestinal and 
respiratory tracts, spread by the fecal-oral route and are shed at high concentrations through feces 
(up to 10
8.7 
50% egg-infectious dose (EID50) per gram feces) and at a lower level by the 
oropharyngeal route (3, 16, 17).  Shedding of the virus in feces contaminates water and the 
environment perpetuating the infection cycle (12).  Many AI viruses are stable and remain 
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infectious in water for periods of up to several months, particularly under favorable conditions of 
fresh to brackish salinity (0–20,000 parts per million (ppm), temperatures below 17C and a pH 
range of 7.4-8.2 (18).  
Adaptation to Poultry:  Galliformes (poultry including: turkeys, grouse, chickens, 
quails, and pheasants) can be infected with AI virus subtypes H5, H6, H7 and H9 by direct 
contact with wild birds or infected poultry and by indirect contact through fomites, vehicles or 
contaminated infectious organic material (19).  AI viruses transferred to Galliformes are often ill-
suited to replicate, transmit and cause disease in their new hosts unless multiple adaptation steps 
take place [6].  Because of the lack of adaptation, transient subclinical infections and the inability 
to spread between birds and flocks, most of these viruses are unable to persist and infection is 
only detected via seroconversion (6, 20, 21).  Due in part to the diversity of circulating AI 
viruses, some are better able to establish themselves in the new host allowing for replication and 
transmission (22).  After transfer to the new host, influenza can evolve rapidly leading to an 
increased possibility of clinical disease and pathogenesis and in rare cases the development of 
highly pathogenic AI (HPAI) (6, 14, 23).  
Changes in AI viruses most indicative of adaptation to Galliformes occur in the major 
surface proteins HA and NA.  Changes at the cleavage site of HA, particularly in subtypes H5 
and H7, are thought to lead to adaptation and also appear to result in increased virulence (6).  
Cleavage of the HA0 protein into HA1 and HA2 subunits is necessary for viral infectivity (24).  
In LPAI viruses HA0 is usually cleaved by trypsin-like proteases which are restricted to the 
gastrointestinal and respiratory tracts (25).  The addition of basic amino acids at the cleavage site 
by mutation or insertion allows a wider range of proteases to cleave HA0 including putative 
ubiquitous proteases such as furin (26).  Ubiquitous proteases can be located in the endoplasmic 
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reticulum and are able to cleave HA0 during the translation process resulting in the production of 
virions that are infectious before they leave the cell, increasing the range of cells that the virus 
can infect leading to mucosal and systemic replication (6).  Systemic replication of the virus 
leads to infection and damage to major organs and tissues, leading to severe disease and death in 
birds (27).  These viruses are considered to show a highly pathogenic (HP) phenotype (28). 
A second major adaptation that takes place upon adaptation to Galliformes is the 
appearance of stalk deletions in the NA gene (6, 29).  The stalk of NA located between the trans-
membrane and globular head domain and serves to keep the enzymatically active globular head 
away from the cell membrane or viral surface (6). The domain is usually hydrophilic and around 
30 amino acids in length and although stalk length is conserved in single subtypes in wild birds, 
length can vary between subtypes (6).  When AI viruses replicate in poultry, deletion of 
approximately 12-20 amino acids occurs (6).  The enzymatic activity of NA removes sialic acids 
from viral and host proteins which is needed for efficient release of virus from host cells by 
preventing virions from sticking to each other (30).  While shortening of the stalk does not 
mutate or disrupt NA’s enzymatically active site, it hampers NA activity by decreasing the reach 
and flexibility of the active site (31).  While it seems contradictory that positive selection would 
choose for a less active protein, it appears changes in HA and NA offset (32).  Stalk deletions in 
NA are typically seen when HA genes have increased numbers of N-glycosolations that reduce 
receptor affinity for sialic acids in turn making the virus less sticky and reducing need for 
efficient sialic acid cleavage (6, 32).  The less effective NA gene can actually lead to improved 
viral spread when a lower affinity HA is present (29, 32).  It is not known at this time whether 
the HA or NA mutation occurs first or the exact advantages these changes confer on the virus 
(33). 
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The adaptation of a wild bird AI virus to a poultry-adapted AI virus is a complex and 
frequently unclear event.  However, rearing and sales practices in developing nations and 
Southeast Asia appear to enable this process. (6).  Many small-scale backyard or village farmers 
raise multiple species in close contact, particularly ducks and Galliformes and public markets sell 
live birds under crowded and at times unsanitary conditions (6).  Evidence suggests that 
domestic ducks are more susceptible to wild duck AI viruses than Galliformes and duck rearing 
often allows access to open bodies of water where wild and domestic ducks can interact (6, 34).  
This leads to a potential chain for wild ducks to pass AI viruses to domestic ducks which in turn 
spread virus to Galliformes.  Japanese Quail and turkeys also appear to serve as bridge species in 
certain geographical areas (6). 
Highly Pathogenic Avian Influenza:  In contrast to LPAI viruses, which are confined to 
the intestinal and respiratory organs and shed through the feces, HPAI viruses replicate 
systemically and are easily shed by nasal and oral routes (35, 36).  HPAI is an extremely 
infectious, highly virulent disease primarily impacting poultry, that can lead to mortality rates of 
up to 100% in the 48 hours following infection (15).  These viruses have emerged following the 
adaptation and mutation of H5 and H7 subtypes of LPAI viruses after transmission from wild 
birds to poultry described above (36).  While all HPAI strains isolated to date have been from H5 
or H7 subtypes, not all H5 and H7 subtypes are highly pathogenic (25).  According to the 2009 
OIE Terrestrial Manual  an AI virus is classified as HPAI when it meets any one of the following 
criteria in chickens (37):  
a)  Changes to the HA proteolytic cleavage site of H5 or H7 including: 1) substitutions of 
the basic amino acids arginine and lysine; 2) insertion of duplications of multiple basic 
amino acids from codons duplicated from the haemagglutinin cleavage site; 3) short 
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inserts of basic and non-basic amino acids from unknown sources; 4) lengthening of the 
proteolytic cleavage site by recombination with other gene segments; and 5) loss of a 
shielding glycosylation site in combination with basic amino acid substitutions.   
b)  Is lethal for 75% or more of eight 4- to 8-week-old susceptible chickens within 10 
days following inoculation with a standardized dose under laboratory settings. 
c)  Any virus that has an intravenous pathogenicity index (IVPI) greater than 1.2. 
Symptoms of HPAI range from “sudden death with little or no overt clinical signs to 
disease with clinical presentations including respiratory signs, such as ocular and nasal 
discharges, coughing, snicking and dyspnoea, swelling of the sinuses and/or head, apathy, 
reduced vocalization, marked reduction in feed and water intake, cyanosis of the unfeathered 
skin, wattles and comb, incoordination and nervous signs and diarrhea (37).” 
Since 1959, 29 epizootics of HPAI have occurred (epizootics are outbreaks of disease 
affecting many animals of one kind at the same time, analogous to the term epidemic applied to 
the human population) (38).  The largest of these outbreaks is the ongoing panzootic of HPAI 
H5N1 that first appeared in domestic geese in China in 1996 as A/goose/Guangdong/1/96 (also 
known as Asian lineage H5N1 and will be referred to as H5N1 hereafter) (38, 39).  Prior to this 
panzootic, HPAI viruses have typically arisen transiently in areas populated with Galliformes 
(36, 40).  The majority of these flare-ups were eradicated by mass culling alone and the 
remainder by a combination of mass culling and vaccination (41).   These outbreaks remained 
limited due to large scale die-offs caused by the high mortality rate of HPAI and the, at the time, 
inapparent ability of HPAI viruses to persist and spread in wild bird populations (40).  Even 
during the first 5 years of the current H5N1 outbreak, minimal evidence for the presence of the 
virus in wild birds was found despite endemic infections in Galliformes and domestic ducks and 
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geese (6, 36).  Since 2002, the paradigm has shifted.  In that year, aquatic and terrestrial birds 
became infected with and died from H5N1 in China, Indonesia, Vietnam and Egypt (6, 36).  In 
2005, 9 years after the emergence of H5N1 in domestic birds, a large outbreak of H5N1 of 
multiple closely related viruses descended from  A/goose/Guangdong/1/96 occurred in migratory 
birds at Lake Qinghaihu in western China (36, 42).  Lake Qinghaihu is an important breeding 
ground for migratory birds that overwinter in Southeast Asia, Tibet and India and other migrant 
birds that congregate from Southeast Asia, Siberia, Australia and New Zealand (42).  During the 
winter of 2006, the variant from this outbreak spread rapidly westward across Central Asia, 
Europe, the Middle East and Africa (43).  Since then the 10 phylogenetically and antigenically 
distinct lineages called clades, plus numerous subclades have emerged (6, 36).  These subclades 
of virus have been maintained in the wild bird population, have become endemic in six countries 
(Bangladesh, China, Egypt, India, Indonesia and Vietnam) and opportunistically spread back to 
domestic poultry making containment difficult (44-46).  From 1997-2011, more than 7,000 
H5N1 outbreaks occurred in 63 countries and from January-March 2012 the WHO confirmed 
164 outbreaks in poultry in 10 countries and 18 outbreaks in wild birds in 10 countries (46).   
Economic Consequences of HPAI:  The mass culling and death of over 400 million 
birds due to H5N1 has led to over $20 billion in economic damage and continued spread 
threatens the global poultry markets which in 2007 produced 83.7 million metric tons of meat 
(8.1 million tons were sold through international trade, 2.1 million metric tons were exported 
from the United States) (46, 47).  Countries with H5N1 outbreaks face reductions in consumer 
sales at home due to fear and lack of confidence along with increased costs due to culling and 
restocking flocks, increasing biosecurity, increasing surveillance and introduction of vaccination 
campaigns (47).  These countries also face the loss of their export markets due to international 
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embargoes and loss of market share due to increased production from uninfected countries (47).  
Importing countries free of H5N1 may also face increased costs due to reduced competition in 
the market place (47). 
The impact has been especially devastating in Southeast Asia where the majority of 
H5N1 outbreaks have occurred and where ¼ of the world’s poultry is produced (47).  In 2003, 
Thailand was the 5
th
 largest poultry exporter in the world (48).  After the emergence of H5N1 in 
2003-2004, the export market collapsed, with metric tons of poultry exports dropping from 
331,044 to 23,953 and income from exports dropping from 22,685 million baht to 1,738 million 
baht resulting in an estimated reduction of 1.5% of GDP growth (48, 49).  Export levels have not 
recovered.   
Thailand, Vietnam and most other Southeast Asian nations have large numbers of small 
scale poultry producers and as much as one third to one half of the population may depend on 
poultry production for income (47).  While the absolute value of the financial losses in this sector 
may not be as large as those in the commercial sector, these producers were most impacted 
relative to assets and income (48).  A 2004 study in Vietnam found that in a typical village 
impacted by an H5N1 outbreak, backyard producers lost on average 2.3 months of production 
and those loses compounded with loss of poultry for family consumption cost each household 
$69-108 (US Dollars), a devastating consequence for areas where income per person averages 
less than $2 per day (50).  Furthermore, with the loss of poultry, the prices of alternative meats 
such as pork rose adding an unknown amount of additional costs (50). 
Transmission to Humans:  Avian influenza also has the potential to severely impact 
human health.  Influenza has established an extremely wide host range, from birds to various 
mammalian species including humans, pigs, horses and dogs (51).  Evidence indicates that all of 
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these mammalian influenza viruses diverged from avian ancestors (3).  Although AI viruses are 
normally species specific and infrequently cross species barriers, direct transmission of AI 
viruses to mammals including pigs, horses, seals, whales, minks and humans has been recorded 
(13, 52).  The specificity and affinity of an influenza virus HA for its sialic acid receptor is a 
critical factor in host tropism and transmissibility (51).  HA binds to host glycans and 
gangliosides that contain terminal sialic acids (36).  Sialic acids bind to cell-membrane sugars 
through α2,3, α2,6, α2,8 or α2,9 linkages (36, 53).  The most common terminal forms of sialic 
acids are N-acetylneuraminic acid-α2,3-galactose (α2,3-SA) and N-acetylneuraminic acid-α2,6-
galactose (α2,6-SA)) and each is expressed in a tissue- and species-specific manner determined 
by sialyltransferases (31, 36, 53).  AI viruses preferentially bind to α2,3-SA which are highly 
expressed in the avian respiratory and intestinal tract while human influenza viruses 
preferentially bind α2,6-SA which are highly expressed by human upper-airway epithelia leading 
to an interspecies barrier (36, 54, 55).  It should be noted that humans express α2,3-SA in the 
lower-respiratory tract on type II pneumocytes, alveolar macrophages, and nonciliated cuboidal 
epithelial cells in terminal bronchioles.  However the relative inaccessibility of this site limits the 
establishment of infection and limits transmission through sneezing and coughing (56, 57).  
Swine tracheal epithelia cells express both α2,3-SA and α2,6-SA causing them to be susceptible 
to both human and avian influenza viruses (36, 58). 
An influenza pandemic occurs when a virus with an antigenically unique HA enters the 
population (59).  Pandemics are of zoonotic nature and arise through reassortment of human 
influenza viruses and those other species or by the direct transmission of a virus from animals to 
humans (36, 51, 60).  Reassortment can occur when two distinct influenza A viruses 
simultaneous infect a single cell (51).  The segmented nature of the influenza genome allows for 
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the mixing of genes and the packaging and production of a novel strain (51).  It is thought that 
most human pandemic viruses were generated in this manner, including the 1957 H2N2 “Asian 
flu” (avian/human), the 1968 H3N2 “Hong Kong flu” (avian/human) and the 2009 swine origin 
H1N1 (avian/swine/human) (35, 36).  The reassortment that led to the 2009 pandemic (and 
possibly the events resulting in the 1957 and 1968 pandemics) occurred in swine which are well 
suited to serve as a mixing bowl due to their susceptibility to human and avian influenza viruses 
(36, 61, 62).   
The 1918 H1N1 “Spanish flu” pandemic appears to have resulted from the direct 
adaptation of an unusual avian precursor (35, 63, 64).  This pandemic is the most devastating on 
record, causing clinically apparent illness in an estimated 500 million people (one third of the 
world’s population) with a case fatality rate of >2.5% resulting in 50-100 million deaths (65).  In 
2005 the US Congressional Budget Office released a report documenting the potential number of 
infections and fatalities and economic consequences that could be expected if a severe pandemic 
of the magnitude of the 1918 pandemic or a milder pandemic mimicking the 1957 or 1958 
outbreaks occurred today (66).  Barring the emergence of an influenza virus with morbidity and 
mortality rates heretofore unseen, the 1918 projections likely represent a worst case scenario due 
to significant medical advances in health care including the development of antibiotics to treat 
secondary pneumonia infections, vaccines, antivirals and respirator technology.  Modeling a 
severe pandemic using an attack rate of 30% and a fatality rate of 2.5% they estimated that in the 
US alone 90 million people would become clinically ill, 18-45 million would require outpatient 
care and 2 million would die.  30% of all workers would become ill, 2.5% would die and 30% of 
all workers would miss an average of 3 weeks due to illness or caring for family members.  This 
could cause the GDP to drop as much as 5% and cost upwards of $675 billion.  Using an attack 
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rate of 25% and a fatality rate of 0.1%, about 75 million would become infected and cause 
100,000 deaths (3,000-49,000 typically die from flu related complications due to seasonal 
influenza).  25% of worked would become ill and miss an average of 4 days.  The GDP would 
decline by 0.5-1% and cost about $70 billion.   
Direct transmission of H5N1 (A/Hong/Kong/156/97) to humans was reported in 1997 
(67-69).  That year, 18 people became infected and 6 died after displaying clinical features 
including fever and upper-respiratory-tract infections typical of influenza infection along with 
severe complications, mainly pneumonia, gastrointestinal manifestations, elevated liver enzymes 
and renal failure (35, 70).  The ability of an avian virus to directly infect humans and the high 
mortality rate sparked fears that a severe pandemic along the lines of 1918 could be on the 
horizon (67).  Since the reemergence of H5N1 in 2003, the WHO has confirmed 608 human 
cases of H5N1 in 15 countries resulting in 359 fatalities (71).  From January-September 2012, 30 
WHO confirmed cases occurring in Bangladesh, Cambodia, China, Egypt, Indonesia and 
Vietnam resulted in 19 deaths (71). 
 The WHO considers an influenza virus to be a pandemic when the following conditions 
are met: 1) A new influenza A virus that infects humans; 2) The population at large has little or 
no immunity to the virus; 3) The virus causes serious illness with high morbidity and mortality 
and 4) transmits easily from person to person (72).  To date H5N1 has not met the fourth criteria 
of sustained human-to-human transmission.  While a handful of cases of H5N1 have occurred 
from caring for or close contact with an infected individual, these make up less than 1% of 
confirmed cases with the remaining 99% occurring as a result of direct transmission from 
infected birds (73-76).  The H5 of H5N1 like other AIV HA preferentially binds to α2,3-SA as 
described above.  The molecular changes in HA necessary to confer aerosol and mammalian or 
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person-to-person transmission are poorly understood.  Recently, Imai et al. and Herfst et al. 
reported the generation of laboratory mutant H5 strains that were able to spread via aerosol 
between ferrets (Ferrets are widely regarded as the best mammalian laboratory small animal 
model for the study of influenza, however it should be noted that like all animal models they are 
imperfect representation of humans and influenza viruses may behave differently in the general 
population) (73, 77).  Imai et al. created a reassortant virus containing the H5 HA from HPAI 
H5N1 A/Vietnam/1203/2004 and the remaining 7 genes from a 2009 pandemic H1N1 isolate.  
After introducing random mutations in the H5 they found 2 mutations in the receptor-binding 
globular head domain known to increase affinity for α2,6-SA, a third that disrupts a N-linked 
glycosylation site and a fourth in the stalk domain.  When this reassortant virus was introduced 
into ferrets, it replicated efficiently, caused lung lesions and weight loss and could be transmitted 
in an airborne manner.  The virus was neither highly pathogenic nor lethal.  Their results show 
that H5 can convert to a form that supports transmission in mammals, but it is unknown if an 
entirely avian H5N1 virus would be transmissible and if inclusion of the remaining 7 H5N1 
HPAI genes (particularly NS1 and PB1) would confer high pathogenicity or lethality. 
Herfst et al. modified the H5 of the HPAI H5N1 A/Indonesia/5/2005 by site-directed 
mutagenesis and serial passage in ferrets.  Unlike Imai et al. the studies in ferrets used a wholly 
avian virus.  After multiple passages the modified H5N1 virus accumulated mutations and was 
able to be transmitted by aerosol or respiratory droplets and cause disease.  5 consistent amino 
acid substitutions were found in the transmissible viruses, 4 in HA and one in the polymerase 
complex protein PB2.  In HA 2 mutations were receptor-binding substitutions known to increase 
α2,6-SA affinity, the third was the same mutation found by Imai et al. at the N-linked 
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glycosylation site and the fourth was at the HA trimer-interface.  The PB2 mutation found is a 
common mammalian polymerase adaptation.   
The results from these two studies indicate that H5N1 may be as few as five amino acid 
substitutions from being able to spread efficiently in humans.  Surveillance data shows that two 
of these mutations have commonly been found in H5N1 isolates indicating that some circulating 
viruses may be as few as three substitutions away from becoming transmissible by an aerosol 
route (78).  This strongly indicates that H5N1 surveillance, prevention and control should remain 
a key focus. 
Control of HPAI:  Controlling HPAI is critical to the health of animals and humans, 
safeguarding the food supply and protecting the economic livelihood of many individuals.  While 
mass culling to stamp out HPAI has been used extensively, the multi-continent spread of the 
disease, maintenance in natural reservoirs, economic costs to producers and regional reliance on 
small scale producers requires a more comprehensive strategy (79, 80).  Furthermore, the OIE 
and the United Nation’s Food and Agricultural Organization (FAO) have taken the position that, 
“For ethical, ecological and economic reasons, it is no longer acceptable to control and eradicate 
disease outbreaks mainly by applying a policy of mass slaughter” and that “Vaccines help to 
improve animal health, public health, animal welfare, and agricultural sustainability, thus 
protecting the environment, maintaining biodiversity, and protecting consumers of animal 
products,” (79, 81).  
Swayne and Suarez of the United States Department of Agriculture (USDA) have 
described a comprehensive approach for an effective HPAI control or eradication program (15).  
First, national surveillance and diagnostic programs should be instituted.  Second, enhanced 
biosecurity measures should be practiced at all levels of poultry production to prevent 
13 
 
 
 
introduction of HPAI.  These measures include eliminating direct contact between poultry and 
wild birds by physical separation, the use of covered pens to prevent contamination from fecal 
matter dropped by migrating birds during flyovers, providing clean water sources and not 
exposing birds to contaminated meat, offal or fomites (6).  Third, poultry farmers should be 
educated to recognize the signs and symptoms of infection and to share information on 
surveillance and control strategies.  Fourth, all AI-infection should be quarantined or moved only 
in a highly controlled manner.  Fifth, stamping-out may be needed in some flocks.  Sixth, is the 
establishment of vaccination programs. 
AI vaccines increase host resistance to disease by the generation of neutralizing 
antibodies and reduce virus shedding curbing spread (79).   Preventative vaccination, emergency 
vaccination or prophylactic vaccination strategies can be appropriate depending on the presence 
or potential presence of HPAI in a region (79, 82).  Preventative vaccines are an option when a 
region is free from disease but at high risk of introduction (79, 83, 84).  This route has been taken 
in France, the Netherlands and Switzerland where certain difficult to contain birds and zoo birds 
were vaccinated due to the risk of migratory birds carrying H5N1 passing through (79).  The 
costs of this strategy may be prohibitive in developing nations that do not have a strong 
veterinary infrastructure (79).  Emergency vaccination is conducted during an active outbreak 
where healthy animals within a certain range of the outbreak are immunized (79).  The area of 
the vaccination zone is determined by transmission rate and spread (79).  Prophylactic 
vaccination is used when HPAI has become endemic in a region (79).  Birds are vaccinated in a 
coordinated and systemic manner against the circulating HA subtype (79).  This strategy should 
involve all levels of poultry producers to be effective and likely needs to be done in conjunction 
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with the eradication of certain flocks (79).  This can be a costly strategy but is necessary when 
large portions of the poultry production industry are threatened.  
Immune Response to Influenza:  Development of effective influenza vaccines requires 
an understanding of the protective immune response generated by infection.  Despite the obvious 
physiologic and structural differences present in the avian and mammalian immune systems, the 
functional characteristics of these systems are well conserved particularly in peripheral organs, 
lymphoid cell functions, division, classes, interactions, specificity, and net effect (41, 85-88).  
The avian immune system generates innate responses and humoral and cell-mediated adaptive 
responses.  Avian T cells homologous to CD3+, CD4+ Th1 and Th2 helper cells and CD8+ 
CTLs have been identified (41).  Chickens have a single gene equivalent to IgG known as IgY 
(IgY exists as a single subtype unlike mammalian IgG which is present in multiple forms) along 
with IgM and IgA equivalents (41, 89, 90).  Since the immunological response to influenza is far 
more extensively characterized in mammals, the details of influenza immunity will be described 
through the human response to infection and appropriate parallels in the avian response will be 
drawn when available. 
Natural infection with influenza can result in decades-long immunity to the original 
infection virus or an antigenically similar strain (91, 92).  Most virus encountered is removed 
nonspecifically by the mucin layer, cilia and protease inhibitors preventing attachment and 
uncoating at the respiratory epithelium (60, 93).  Influenza virus that escapes these basic defense 
mechanisms encounters other facets of the innate immune system.  During an infection, the 
innate immune system recognizes pathogens as foreign bodies through microbial-associated 
molecular patterns (MAMPs) characteristic of infectious agents through pattern-recognition 
receptors (PRRs) such as Toll-like receptors (TLRs) and generates an appropriate response (94-
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96).  When influenza infects and replicates in cells, the viral RNA produced activates the RIG-
I/IPS-1 pathway (97).  When plasmacytoid dendritic cells endocytose virus and incorporate them 
into their lysosomes, the freed viral RNA is recognized by the TLR7/MyD88 pathway which 
induces type 1 IFN production (97).   
Both the mucosal and systemic arms of the humoral immune system play roles in 
resistance to influenza infection with secretory IgA (sIgA) involved in protection of the upper 
respiratory tract and serum IgG in the lower respiratory tract (91).  Over the course of an 
infection in humans, antibodies to all major viral proteins are produced with those specific for 
HA and NA being the most critical (91, 98, 99).  At high enough concentrations in the 
respiratory tract, strain specific anti-HA antibodies completely neutralize influenza virus 
infection while anti-NA antibodies slow the spread of infection by hampering viral release from 
infected cells (100).  While antibodies to the well conserved M and NP antigens are generated, 
they are not protective (100, 101). 
Mucosal immunity is important in combating influenza infection as mucosal tissues are 
the port of entry for the virus.  sIgA, and to a lesser extent IgM, are the major neutralizing 
antibodies towards mucosal pathogens and can prevent entry and act intracellularly to impede 
viral replication (91, 102).  During primary infection, locally produced HA and NA-neutralizing 
sIgA are present in nasal secretions and IgM, IgG and IgA can be detected in nasal washes with 
IgM and IgA being most prevalent (91, 103-106).  Furthermore local influenza IgA response 
usually lasts 3-5 months, memory committed IgA secreting B cells can be detected and IgA is 
the primary Ig subtype detected in secretions after secondary infections (91, 106-108). 
Anti-HA antibody levels in serum are the most widely used measure of protection against 
influenza infection and a hemagglutination inhibition titer of 40 is typically considered protective 
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(109).  This antibody titer is achieved in about 80% of human subjects following infection (91).  
In humans influenza IgM, IgG and IgA are present in infected individuals and serum levels of 
anti-HA and anti-NA antibodies correlated with resistance to and recovery from infection (91, 
103, 110-113).  Within two weeks of primary infection IgM, IgG and IgA can be detected with 
IgG and IgM being the most abundant.  IgA and IgM levels peak and decline at the two week 
mark while IgG does so at approximately 4-6 weeks.  During secondary responses the dominant 
isotypes are IgG and IgA (91, 106, 114).  
While cell-mediated immunity does not play a significant role in sterilizing influenza 
immunity it has a crucial role in clearance of virus, recovery from infection and the reduction of 
influenza complications such as lethal secondary infections (91, 115).  Influenza-specific CD8+ 
cytotoxic T lymphocytes (CTLs) are found in the blood and lower respiratory tract of infected 
individuals and work in concert with influenza specific antibodies and complement to lyse 
influenza infected cells (91, 116-119).  CTL response appears 6-14 days after infection and 
subsides by day 21 post-infection (91, 120).  The majority of CTLs target epitopes on the 
nucleoprotein (NP) and the acid polymerase (PA) gene, a much lower proportion target basic 
polymerase subunit 1 (PB1), non-structural protein 2 (NS2) and matrix protein 1 (M1) and a very 
rare number appear to target HA (115, 121).  Additionally, certain CTLs can cross-react between 
influenza A subtypes (91).  Memory CTLs are cross-reactive, appear about 2 days earlier in 
secondary infection than their primary counterparts, peak at 14 days and persist until returning to 
baseline at 6 months (91, 120, 122).  While memory CTL numbers are not proportional to the 
rate of infection and illness clearance they do correlate to the pace of viral clearance (115, 119).  
Despite the inability to prevent illness, vaccines that induce memory CTL responses may play 
key roles in lessening the severity of highly pathogenic influenza infections (115). 
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CD4+ T cell responses to influenza infection are predominantly Th1 based leading to the 
secretion of IFN-γ and IL2 (93, 123).  IFNγ and IL-2 drive complement-activating IgG2a 
antibody production by B cells and enhance proliferation of CTLs (93, 124).  It is unclear to 
what extent CD4+ T cells are necessary or responsible for the development of CTL responses 
during primary infection but it has been demonstrated that they are needed for proper memory 
CTL response during secondary infection (115, 125-129).  Studies inhibiting Th1 responses 
show that Th2 based responses, leading to the secretion of IL4 and IL5 which induces B cells to 
produce non-complement activating IgG1, IgA and IgE, results in a much less robust immune 
response to influenza (93, 124).   
Live-Attenuated vs. Inactivated Vaccines:  A significant choice in vaccine 
development is whether to use a live-attenuated or an inactivated vaccine.  Live-attenuated 
vaccines mimic virulent viruses and bacteria and trigger an immune response by the production 
of an asymptomatic infection (95, 130).  In both human and veterinary practice live-attenuated 
vaccines generally require only one application, induce major antibody production within 10 to 
14 days, stimulate cell-mediated immune responses and use a small amount of antigen (131).  
While live-attenuated vaccines are generally safe, they do produce active infections and can 
produce slight signs of infection or severe infection when not properly attenuated (131).  Risks 
associated with their use include failure to fully inactivate the pathogen, residual virulence of the 
attenuated agent, spread to other subjects and establishment of infection in the 
immunosuppressed (132).  Care must be taken to administer live vaccines to only healthy 
subjects as vaccinating the ill may result in reduced antibody production or cause an 
exacerbation of the concomitant disease (131).  Additionally, antibiotics or antivirals that would 
clear the vaccine before immunity can be established must be avoided (131). 
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Often, an attenuated form of a pathogen can be difficult or unfeasible to attain, unstable, 
have a risk of reverting to a virulent form or cause burdensome side effects (130).  An alternative 
to a live-attenuated vaccine is an inactivated vaccine consisting of either whole inactivated 
viruses or bacteria or a purified component of the pathogen such as a protein or carbohydrate.  
Inactivated vaccines are advantageous because they do not cause disease and often have a longer 
shelf life than live vaccines (131).  Inactivated vaccines are designed to be less reactogenic to 
reduce adverse reactions; however this results in decreased immunogenicity [52].  These 
antigens do not replicate, are less immunogenic and are often administrated by an unnatural route 
of exposure such as intramuscular injection and usually lack MAMPs.  As a consequence, these 
antigens often fail to stimulate a protective reaction in the vaccinated subject (95, 130).  This 
leads to drawbacks including the need for an increased doses or a greater amount of antigen in 
each dose of the vaccine leading to increased production costs, reduction in compliance and 
more stress to the subject (131).  High levels of antibodies are not usually seen until after a 
booster and the vast majority of antibody produced is IgG while live vaccines lead to the 
generation of a wider range of subtypes (131). 
Currently Available Influenza Vaccines: Each seasonal influenza vaccine contains 
15ug each of HA from H1N1, H3N2 and an influenza B strain.  Currently approved vaccines for 
human use are classified as either cold-adapted live attenuated virus vaccines (LAIV) or 
inactivated vaccines (93, 133).  The LAIV licensed as Flumist® in the United States was 
approved in 2003 for use in healthy individuals between the ages of 2 and 49 (93).  This LAIV is 
administered intranasally, mimics the natural influenza infection process, induces sIgA and IgG 
antibody production, induces CTL responses and provides cross-protection amongst some 
variant types of virus (93, 106, 134, 135).  Safety of this vaccine has not been established for 
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pregnant women, the immunocompromised, those with existing medical conditions that increase 
risk for influenza complications and other highly susceptible groups such as infants and those 
aged over 65 (136).  Therefore the populations at highest risk for severe influenza infections are 
not approved to receive this vaccine despite its efficacy in healthy individuals.  Additionally, 
LAIVs are not likely to be used in an avian outbreak or in a prepandemic/early pandemic human 
outbreak due to the small but extremely dangerous possibility that the novel HA included in the 
LAIV could recombine with a circulating wild-type virus and create a fully virulent virus 
containing the HA from the vaccine strain (133). 
Parenterally administered inactivated influenza vaccines include the split-product, 
subunit and whole-virion vaccines. These are the most commonly used influenza vaccines and 
have been approved for use in individuals ages 6 months or older.  When inactivated influenza 
vaccines are used, innate responses are weakly or not at all stimulated, especially in the case of 
subunit vaccines (137).  When a whole-virus inactivated vaccine is used the TLR7/MyD88 
pathway is activated; however, without active production of viral RNA the RIG-I/IPS-1 pathway 
is not (137).  Studies in mice show subunit vaccines lack efficacy in naïve animals that have 
never been infected with influenza suggesting that subunit vaccines may not be able to provide 
necessary protection levels in the case of a pandemic when the entire population is naïve to the 
new influenza strain (137).  While whole-virion vaccines are more immunogenic, split and 
subunit vaccines are more commonly used due to a lower incidence of injection site reactions 
(91).  Inactivated influenza vaccines induce HA-specific serum IgG antibodies and are 60-100% 
effective in the prevention of morbidity and mortality from homologous viruses in adults, 
however they offer little to no protection against variant strains (91, 93, 106, 113, 134, 138, 139).  
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However, inactivated vaccines have reduced efficacy in young immune-naïve populations and 
are only 30-50% effective in preventing morbidity and mortality in those over 65 (91, 140-142) 
As described above, T helper responses to natural infection with influenza are primarily 
Th1 based.  As the LAIVs mimic natural influenza infections they too stimulate Th1 responses 
(124).  On the other hand inactivated split or subunit vaccines generate a predominantly Th2 
response with low IgG2a:IgG1 ratios (124, 143).  In general inactivated whole-virus vaccine are 
more immunogenic than split influenza virus vaccines and induce a primarily IgG2a response 
indicative of a Th1 response in mice (143).  Technologies such as the use of adjuvants (described 
below) must be developed to activate the innate and adaptive immune system and drive Th1 
immunity in inactivated influenza vaccines. 
As in humans and other mammals, protective immunity to influenza induced by 
vaccination is primarily antibody mediated in avian species.  Neutralizing anti-HA IgY blocks 
viral attachment and prevents infection and partial protection is generated by anti-NA antibodies 
(41).  Measurable immune responses are generated to nucleoprotein, polymerase and matrix 
protein, but again do not lead to protective immunity (41, 144, 145).  While not extensively 
examined, limited studies indicate cellular immunity can limit the severity and duration of 
disease following HPAI virus infection in chickens and turkeys (41). 
Almost all (95.5%) AI vaccines manufactured for use in poultry are inactivated whole-
virus vaccines administered subcutaneously in the neck or intramuscularly in the thigh (38, 41).  
To boost immunogenicity, these vaccines are adjuvanted in water-in-oil or water-in-oil-in-water 
emulsions (41).  Vaccines have been used to control LPAI since the 1970s and in recent years 
have been used to fight LPAI strains of H5 and H7 in the United States, Italy, Mexico, 
Guatemala and El Salvador (38).  From 2002-2012 113 billion doses of AIV vaccines were used 
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against HPAI (38).  Ninety-nine percent of these vaccines were used in China, Egypt, Indonesia 
and Vietnam against H5N1 and consistently prevented clinical disease and mortality in poultry 
allowing for the maintenance of livelihood and security standards during disease outbreaks (38).  
However, a troubling development has been seen in Egypt where agricultural authorities have 
used vaccination against endemic H5N1 without success (146).  Even three doses of inactivated 
oil-whole-virus emulsion vaccines against the circulating H5N1 clade failed to provide the 
proper level of protection against the virus (146).  Evidence shows that maternal antibodies 
transferred through the yolk sac neutralize the vaccine before it can stimulate a protective 
immune response (146).  Delaying vaccination until after maternal antibodies disappear runs the 
risk of exposure to the endemic circulating virus. In these cases, vaccines that effectively 
stimulate antigen processing and presentation may need to be considered. 
The remainder of AI vaccines are recombinant H5 expressing fowlpox or Newcastle 
disease virus-vectored vaccines (41).  Live AIV vaccines are not recommended for use due to the 
aforementioned potential to mutate into an HPAI and for the need to eradicate LPAI viruses from 
poultry populations prior to vaccination (41).   
Mucosal vaccination by oral or intranasal inoculation using inactivated influenza 
vaccines would be ideal for both human and poultry populations.  In addition to inducing 
antigen-specific systemic and mucosal immunity and the induction of secretory IgA, mucosal 
vaccination would increase compliance in needle-phobic humans, allow for easier administration 
in poultry and decrease the risk of disease spread due to contaminated syringes (147, 148).  
Unfortunately most soluble antigens are not efficiently taken up when administered by mucosal 
routes and can induce immune tolerance (147, 149).  As of this time oral or intranasal inactivated 
influenza vaccines are not commercially available. 
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Vaccine Production:  Annually, 250-300 million doses of trivalent influenza vaccines 
for humans  are  produced in embryonated hen’s eggs through a collaborative process involving 
WHO Collaborating Centers and vaccine manufacturers (150).  Year-round, sentinel physicians 
collect nasopharyngeal swabs from patients displaying influenza illness and send the samples to 
National Influenza Centers for isolation and identification of subtype (150).  When a new strain 
is found, it is sent to a WHO Collaborating Center for Influenza Reference and Research.  As 
influenza viruses primarily circulate in winter months, WHO Collaborating Centers review 
circulating strains for the Northern hemisphere in February and the Southern hemisphere in 
September (150).  After analysis of epidemiological data, the WHO selects variants to be 
incorporated into the next season’s vaccine formulation beginning a 6 month-long manufacturing 
process.  First the new virus strains must be adapted to reduce virulence and maximize growth.  
This has classically been accomplished by preparing genetic reassortments using the field strain 
and H1N1 A/PR8/34 (PR8) or PR8-like master strain that grows to high titers in embryonated 
eggs (150).  High-growth hybrids containing the HA and NA from the field strain and internal 
components from the master strain are isolated and used in the vaccine strain (151).  In recent 
years this step has been aided by the use of reverse genetics (152).  After vaccine strains are 
identified, potency reagent preparation occurs.  This step involves the generation of antibodies 
and reagents by the WHO Collaborating Center for distribution to manufacturers to ensure 
accurate measurement of vaccine production and dosage (151).   
After the vaccine strain is distributed, manufacturers optimize growth conditions in eggs 
and begin bulk manufacture.  Vaccine virus is injected into 9-12 day old specific pathogen free 
(SPF) fertilized hen’s eggs and incubated for 2-3 day.  The egg white is harvested and virus is 
separated, killed chemically (typically with formalin) and concentrated.  To produce a split or 
23 
 
 
 
subunit vaccine, the purified particles are treated with the detergent Triton and HA and NA are 
isolated and further purified.  The vaccines are tested for sterility and amount of antigen (15ug 
HA/strain and a detectable amount of NA) then for safety in animals (153).  Some countries, 
including those in Western Europe participating in European Medicines Evaluation Agency 
(EMEA) require each new influenza vaccine formulation to be evaluated in a clinical study 
(154). 
Veterinary vaccine manufacturers produce a number of inactivated avian influenza 
vaccines for use in poultry.  Vaccines are available for clades of subtypes H5N2, H7N3, H5N9, 
and H5N1 (155).  Additionally reverse-genetics based vaccines are produced for H5N1 with 
altered H5 cleavage sites to reduce pathogenicity in eggs (155).  The manufacturing process is 
similar to influenza vaccines produced for humans with the exception of an allowance for the use 
of specific antibody negative eggs and the use of non-purified allantoic fluid containing whole 
virions to reduce production costs (41, 156).  According to OIE guidelines, licensed avian 
vaccines for high pathogenicity strains should be tested in a minimum of 24 SPF chickens per 
group with a challenge virus dose that causes 90% or more mortality in non-vaccinated birds 
(typically 10^6 chicken embryo infectious  doses (EID)) (156).  For low pathogenicity strains 
where mortality is not typically a complication from infections, a statistically significant 
reduction in shedding titer and/or number of birds shedding virus from the oropharynx or cloaca 
should be seen in the vaccinated groups (156).  While HA doses as low as 0.4ug have been 
shown to protect chickens from challenge, OIE and USDA researchers and the OIE recommend 
that minimum antigen per dose be 50 50% protective doses (PD50) or 3ug hemagglutinin as the 
best protection was achieved with 3-8ug of antigen (41, 156-158).  Hemagglutination inhibition 
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titers in vaccinated birds should be at least 1:32 to protect from mortality and 1:128 to result in a 
reduction in challenge virus replication and shedding (156, 157). 
The egg-based influenza vaccine production system has proven to be a reliable way to 
produce vaccines since the 1950s.  However, drawbacks exist particularly pertaining to pandemic 
preparedness.  Viral growth in eggs can be unpredictable and optimization steps lead to delays in 
production.  Even in the best-case scenarios, the egg-based production system takes a minimum 
of 28 weeks from isolation of a new pandemic strain until release of the vaccine (153).  During 
the 2009 swine H1N1 pandemic, the United States Department of Health and Human Services 
set a 6-month goal for the production and delivery for the pandemic vaccine.  While this goal 
was met, production was slowed due to a portion of the influenza vaccine production capacity 
already being in use for the 2009-2010 seasonal influenza vaccine and the pandemic vaccine was 
not available until after the pandemic peaked (159). 
Until recent years, the egg supply was set up only to support seasonal vaccine production 
leaving periods of 3-4 months where eggs were not available (153).  To address this concern, the 
US government has awarded contracts to manufacturers to maintain a year-round production egg 
supply (153).  Even with a more consistent egg supply, the current 300 million dose vaccine 
production capacity requires approximately 900 million eggs which must be housed under SPF 
conditions (153, 160).  In a pandemic situation, the best case scenarios where the entire world’s 
vaccine production capacity could be used, the virus grows to high titers in eggs and a single 
15ug HA dose achieves efficacy, 900 million-3 billion doses could be produced, enough to 
protect roughly 13-43% of the world’s population (160, 161).  Furthermore, avian influenza is 
infectious to embryonated eggs and egg laying flocks.  In the case of a severe avian influenza 
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pandemic, large scale die-offs of birds due to infection or mass culling could severely strain 
capacity.  
Cell Culture Vaccines:  Since the advent of the Salk’s killed poliovirus vaccine, most 
viral vaccines have been produced in cell culture systems (162).  To date, there are licensed 
vaccines for at least 14 different viral diseases (162).   The most frequently used cell lines for 
development and production are: Vero (African green monkey cell line), WI-38 and MRC 5 
(secondary human lung fibroblasts), Madin-Darby canine kidney (MDCK), chick embryo 
fibroblast cells (CEF), PerC6 (immortalized human cell line) and primary monkey kidney (PMK) 
cells (162).  In the USA vaccines produced in the following cell lines have been approved: CEF 
(measles, mumps, rabies, tick-borne encephalitis), Vero (Japanese encephalitis, poliovirus, 
vaccinia, rotavirus), WI-38 (rubella), MRC5 (hepatitis A, rabies, herpes zoster) (162).  For 
influenza vaccines the European Union has approved a  subunit vaccine produced in MDCK 
cells and Austria and the Czech Republic have approved an inactivated, split influenza vaccine 
produced in Vero cells (162).   
The cell culture-based system offers several advantages.  Established cell lines are fully 
characterized and come from uniform cell banks ensuring that all are identical unlike the 
differences between individual embryonated eggs (163).  These cell lines use well established 
protocols and can be grown in a controllable, standardized manner.  The production process uses 
a closed fermenter system which limits the risk of contamination and can eliminate the need for 
the addition of antibiotics (163).  Closed production systems are advantageous in a pandemic 
context because they are better suited and more easily adaptable to meet the higher biosafety 
levels needed when using unmodified pandemic strains especially in comparison to the open 
infection and harvesting process for the egg-based system (163).  Additionally, reagents for cell 
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culture can be stocked and stored months in advance and frozen cell lines are available for 
immediate use enabling vaccine production at any time in contrast to eggs which requires months 
of preparation and exact timing of chicken flocks (163).  Furthermore, production capacity using 
suspension cell cultures are limited only by the number and volume of bioreactors and can be 
scaled accordingly.   
Vaccine manufacturers in the US, Japan and Europe have employed the following cell 
lines for development and manufacture of influenza vaccines: adherent Vero, adherent and 
suspended MDCK, PerC6, EBx (chicken embryonic stem cell) and EB66 (duck embryonic stem 
cell) in suspension (163).  In response to a 2006 HHS request for proposals, 6 vaccine 
manufacturers requested and were awarded contacts from the US government totaling more than 
$1 billion to develop seasonal and pandemic cell-based influenza vaccine platforms (160, 162).  
4 of these contracts are still active and 3 systems have reached the clinical trial phase.  
Inactivated seasonal vaccines produced by Baxter in Vero cells and by Novartis in suspension 
MDCK cells have completed Phase III clinical trials and applications for licensure are expected 
to be completed in the near future (162).  Additionally, Baxter and Novartis H5N1 pandemic 
vaccines have completed a Phase I clinical trial and a Phase I trial for Baxter’s H9N2 pandemic 
vaccine has been initiated (162).  Currently an inactivated GlaxoSmithKline seasonal vaccine 
produced in EB66 suspension cells has completed Phase I testing and an H5N1 pandemic 
vaccine trial is underway and MedImmune is in the preclinical testing stages for a seasonal live-
attenuated vaccine produced in adherent MDCK cells (162).   
MDCK cells were first isolated and established as a cell line in 1958 and are one of the 
most investigated, characterized and utilized epithelial cell lines ever.  Even after 30 years of in 
vitro culture, MDCK cells have retained functional characteristics of renal epithelium including 
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collecting ducts (164).  Influenza viruses replicate to high titers in MDCK cells which are 
permissive for all current human, avian, porcine and equine vaccine strains (163).  MDCK have 
long been the laboratory standard for isolating and replicating influenza virus and are used by the 
majority of the national Global Influenza Surveillance Network laboratories, all WHO 
Collaborating Centers and reference laboratories and have been selected by multiple 
manufacturers for vaccine production trials (162, 163).  When influenza viruses are grown in 
chicken eggs, an adaptation process must take place leading to viral selection of mutants at the 
antibody sites on HA resulting in variances in antigenicity between the original isolate and the 
passaged virus (163, 165-167).  In MDCK cells, this selective process does not take place, 
ensuring consistency between viral isolates and vaccine strains (163, 165).  This retention of 
antigenic characteristics in HA may lead to increased vaccine efficiency (168).   
In recent years studies have addressed concerns relating to vaccine production in MDCK 
cells, mainly production limitations due to adherent properties and safety.  Standard MDCK cells 
are highly adherent and the need for large amounts of surface area or carriers limits the ability to 
scale up production.  MDCK cells usually require tissue culture medium supplemented with 
serum to attach and grow on surfaces increasing the risk of contamination with animal viruses 
and transmissible spongiform encephalopathies (163).  Adherent cells also require trypsin or 
protease treatment to detach adherent cells during passage further complicating the scaling up 
process.  Moreover, in adherent MDCK cells influenza only buds from polar surfaces containing 
microvilli limiting virus yield (163).  
At the industrial level, suspension cells offer significant advantages to adherent cells 
lines.  When cells grow freely in tissue culture medium, adherence factors from serum 
supplements are not required, detachment steps utilizing trypsin or proteases are not needed 
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when passaging cells and suspension cells can be easily expanded by dilution into fresh medium 
enabling rapid expansion in bioreactors.  Currently Novartis’s MDCK suspension cell line 
MDCK 33016-PF is used for the manufacture of a seasonal influenza vaccine in Europe 
(Optaflu®) and a pandemic H1N1 vaccine (163).  These cells are grown in serum-free medium 
with minimal supplementation, preserve antigen specificity, are resistant to other viruses 
minimizing the risk of contamination with other respiratory pathogens, are not permissive for 
most common avian viruses and do not support prion replication (163, 169-171).  Extensive 
studies show that the Optaflu® cell culture-based vaccine is equally well tolerated, immunogenic 
and safe as egg-based vaccines and has shown 83.8 % efficacy in clinical settings (163, 172-
175). 
These studies indicate that MDCK cells are an ideal cell line for use in the development 
of new influenza vaccines. 
Adjuvants:  Increasing the potency of influenza vaccines is especially critical in the 
response to an emerging strain or pandemic.  First, producing a vaccine that generates a stronger 
immune response lowers the amount of antigen needed per dose shortening the production time 
(152).  Second, a more potent vaccine may negate the need for a second dose to achieve optimal 
protection again extending the vaccine supply (152). 
To attain long-lasting protective immunity the vaccine needs to stimulate a local response 
at the injection site and a systemic immune response including activation of antigen presenting 
cells, production of cytokine and trafficking of lymphocytes [50].  As described above, 
inactivated vaccines often fail to sufficiently activate the immune system.  To overcome this 
challenge, adjuvants may be added to artificially stimulate immune responses (95).  Adjuvants 
are derived from a variety of sources and typically are not or are weakly immunogenic on their 
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own, but work to boost immune responses to the vaccine components (94).  These molecules can 
act as carriers or depots, target specific immune responses, or serve immunostimulatory or 
immunomodulatory functions (176).  This lessens the amount of antigen and injections needed 
making the vaccine more cost effective (94, 95, 176).  Additionally, certain adjuvants can shift 
immune responses to tailor a more appropriate form of immunity (95). 
An ideal adjuvant possesses several important qualities.  First, it should elicit a proper 
immune response, such as an appropriately balanced Th1/Th2 response or stimulate the innate 
immune system via TLRs.  Second, it should be compatible with the antigen to ensure a physical 
interaction.  Third, it must be safe to use in an animal or human subject.  Fourth, it must be stable 
and cost effective (94).  Adjuvants currently in production or experimental vaccines include 
multiple aluminum salts (collectively known as alum), oil emulsions, saponins, immune-
stimulating complexes (ISCOMs), liposomes, microparticles, polysaccharide derivates, 
cytokines, and  bacterial derivatives (176).   
A limited number of adjuvants have been approved for use in human vaccines. As of July 
2012, only two adjuvants have been approved for use in the United States, one is alum in the 
forms of aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate or mixed 
aluminum salts and the second is AS04, a combination of monophosphoryl lipid A and alum 
(177).  Alum is the most commonly used adjuvant in human vaccines and has been included in 
tetanus, diphtheria, pertussis, hepatitis A, and inactivated polio vaccines over the course of more 
than 60 years and has an excellent safety record (94, 177).  Alum exerts its adjuvant properties 
by multiple mechanisms.  Alum has long been believed to create a depot effect, allowing for the 
retention of antigens at specific site resulting in slow release and a prolonged immune response 
and can keeps antigens in a particulate form which enhances phagocytosis by antigen presenting 
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cells (94, 178).  Additionally alum can induce maturation of monocytes and macrophages and 
activate the NLRP3 portion of the inflammasome which leads to the production of pro-
inflammatory cytokines (94).  MS04 is a combination of alum and monophosphoryl lipid A 
(MPL), a derivative of lipopolysaccharide (LPS) from Salmonella Minnesota R595 (94).  MPL 
signals through TLR4 and drives Th1 responses while tempering Th2 responses (179).  MS04 is 
currently used in certain hepatitis B (HBV) and human papilloma virus (HPV) vaccines (177). 
Despite its safety and frequency of use, alum is a relatively weak adjuvant with 
significant drawbacks (95, 130).  In human and animal studies it has been shown that alum is not 
a potent stimulator of antibody production when incorporated into recombinant protein vaccines 
(180).  Alum also biases towards Th2 responses instead of a Th1 response and results in minimal 
or no generation of CTL responses (132, 181, 182).  Furthermore, alum has been shown to 
induce IgE responses and in some cases cause IgE-mediated allergic reactions (183, 184).  These 
factors make alum particularly unfavorable as an adjuvant for parasitic or viral infections such as 
influenza necessitating the development of alternative strategies. 
Three adjuvants have been approved for use in human influenza vaccines in Europe.  
Two, AS03 and MF59 are oil-in-water emulsions, microdroplets of oil in water stabilized by 
surfactants (94, 95).  In these two adjuvants the oil utilized is squalene, a type of purified fish oil 
commonly derived from shark liver oil (185).  AS03 is used in the influenza vaccine 
Prepandrix® and MF59 is used in Fluad®, an influenza vaccine used in adults over age 65 (94).  
The third, sold as Inflexal®, is a virosome based vaccine consisting of a reconstituted influenza 
virus envelope that does not contain genetic material or non-surface proteins (94, 186).  
Due to poor uptake of antigen, adjuvants are needed for many mucosal vaccinations to be 
effective.  The bacterial enterotoxins cholera toxin (CT) from Vibrio cholerae and heat labile 
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enterotoxin (LT) from E. coli are the two most commonly used experimental mucosal adjuvants 
(147).  Despite successful use in mice, these adjuvants are unlikely to be used in human vaccines 
due to safety concerns (147).  When CT was delivered in quantities as low as 2.5ug as an 
influenza vaccine adjuvant in mice, antigen-specific IgE responses were induced raising 
concerns of hypersensitivity reactions, along with massive infiltration of mononuclear cells to 
the lungs (187).  CT and its derivative form have also been shown to redirect vaccine delivered 
antigens to the olfactory nerve and bulb of the brain in mice which has the potential to cause 
severe neurological reactions (147, 187-189).  LT and its nontoxic derivatives have shown 
negative side effects, primarily the development of Bell’s palsy (a weakness or paralysis of facial 
muscles resulting from damage or trauma to the facial nerves) after intranasal vaccination (147).  
During the 2000-2001 influenza season an inactivated virosomal-subunit mucosal vaccine 
containing LT was used in Switzerland.  It was withdrawn after it was found to increase the risk 
of Bell’s palsy at least 19 times, a rate which would lead to 13 excess cases per 10,000 vaccines 
(190).  Phase I clinical trials for both an HIV and tuberculosis vaccine utilizing the non-toxic 
mutant LT LTK63 also had incidents of Bell’s palsy in healthy individuals (191).  Alternative 
less toxic adjuvants must be developed for mucosal vaccines to advance. 
Naturally derived immunostimulatory molecules such as cytokines are attractive 
alternatives to the above described adjuvants.  Cytokines are master regulators of the immune 
system that guide the innate and adaptive immune responses and are responsible for establishing 
and maintaining immunological memory (192).  The makeup and extent of the cytokines 
response to an antigen play key roles in determining if the host will mount an effective immune 
response (180).  Cytokines and chemokines at the site of infection send inflammatory signals that 
activate resident phagocytes and recruit phagocytic cells, regulate dendritic cell function, 
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stimulate antigen presentation and drive T and B cell recruitment, effector function and 
differentiation into memory cells (192).  The ability of cytokines to drive favorable immune 
responses has been exploited in vaccine adjuvant design.  Recombinant protein and DNA 
expressed cytokines have been tested in DNA vaccines, tumor vaccines and killed and live 
attenuated viral vaccines (96, 193-195).  Additionally cytokines have shown great potential as 
adjuvants for intranasally delivered vaccines and warrant further exploration (147). 
Vaccines and Adjuvants in Agricultural Practice:  Vaccines are commonly used in the 
poultry industry and a wide range of livestock animals including cattle, pigs, sheep, goats and 
farm raised fish.  While these vaccines have the same overall goals as human vaccines and work 
in a similar manner, animal rearing and trade practices present unique challenges (142).  
According to the United States Department of Agriculture (USDA) biologicals such as vaccines 
must be “pure, safe, potent and efficacious and not be worthless, contaminated, dangerous or 
harmful” and “free from properties causing undue local or systemic reactions when used as 
recommended by the manufacturer” (132).  Practical concerns mandate that a vaccine, along 
with any adjuvant that may be included, have minimal adverse reactions, not significantly impact 
the comfort and welfare of the animal, not hinder growth and reproduction rate, not result in 
carcass blemishes or a decline in meat quality, and be easily applicable to large numbers of 
animals in a short time (142).  Additionally vaccines must be cost-effective, especially when the 
production of tens of billions of doses may be required annually  (180).  Most current vaccines 
meet these goals but there is room for improvement (as described below). 
The previously discussed vaccination systems, live-attenuated vaccines, inactivated 
vaccines with alum adjuvants and inactivated vaccines with oil adjuvants, all have shortcomings.  
With live attenuated vaccines, the response to infection can result in fever with a reduction of 
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feeding, dullness and reduced milk production (142).  Alum adjuvants often fail to stimulate 
proper, robust immune responses and site reactions can cause irritation and granulomas leading 
to animal stress and discomfort (180).  While oil-based vaccine adjuvants, in particular MF59, 
have shown promise and in some cases gained approval for use in human vaccines, they are not 
commonly used in poultry vaccines due to side effects and site reactions (180, 196, 197) 
Parenteral administration of vaccines of poultry is typically done by subcutaneous 
injection in the nape of the neck, intramuscularly in the thigh or by wing web injection.  This 
additional labor costs an average 5 to 7 cents per bird; a significant added expense considering 
most vaccines alone cost 5 to 10 cents per dose (157, 198).  These costs rise quickly in mass 
production commercial facilities.  Alternative methods such as in ovo vaccination or posthatch 
vaccination through the respiratory or alimentary tracts have been proposed (157).  In the United 
States, most broiler chickens are vaccinated in ovo for the avian herpesvirus Marek’s disease 
(157).  While proof-of-concept studies have shown that inactivated, adenovirus and Newcastle 
Disease Virus-vectored AIV vaccines can be effective when administered in ovo, neutralization 
of the vaccine by maternal antibodies in areas where AI viruses are endemic is a significant 
concern (146, 157, 199-201). 
Alimentary administered vaccines can be distributed in feed or drinking water.  A single 
study demonstrating protection from infection via an avian influenza vaccine administered 
through water has been conducted, however to achieve protection, high doses of vaccine had to 
be delivered up to 9 times (157, 202).  Currently, no drinking water or feed AI vaccines are 
licensed (157). 
Vaccines delivered by spray or aerosol are ideal for mass application and are currently 
used in poultry in the US and many parts of the world for infectious bronchitis virus (IBV), 
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Newcastle disease virus (NDV), avian metapneumovirus and many Mycoplasma galliseptum 
vaccines (203-205).  These vaccines are either mass applied in spray cabinets in hatcheries or by 
backpack sprayers in production houses (157).  Mucosal vaccination also offers the advantages 
of conjunctival and upper respiratory tract exposure which can induce mucosal and systematic 
immune responses and can halt infection at the viral entry site (157, 205-209).  It should be noted 
that the three viral vaccines are either attenuated or delivered via live viral vectors.  As 
vaccination with live-attenuated AI viruses is not acceptable for AI, inactivated vaccines must be 
used.  Others have found that that intranasally applied whole inactivated AI vaccines are poorly 
immunogenic in mice and chickens (205, 208, 210).  de Gues et al. found that adjuvanting whole 
inactivated AIVs with alum, chitosan, cholera toxin B subunit and Stimune® (a commercially 
available water-in-oil emulsion) did not improve immunogenicity indicating that testing of 
alternative adjuvants are necessary for intranasal or aerosol vaccination (205).  
Membrane-Bound Immunomodulators as Adjuvants in a Cell Culture-Based Avian 
Influenza Vaccine:  To address the shortcomings of current influenza vaccines outlined above, 
this study examined subcutaneous or intranasally delivered inactivated, whole virus vaccines 
produced in a mammalian cell culture system, bearing membrane-bound bioactive 
immunomodulatory adjuvants.  To accomplish this, fusion constructs containing the cytoplasmic 
and transmembrane domains of the influenza surface proteins HA or NA and the 
immunomodulator of choice were generated using a eukaryotic expression vector.  These 
constructs were stably transfected into MDCK cells and produced immunomodulators that were 
directed to lipid rafts, anchored to and then expressed on the cell surface (Fig. 1).  Afterward, 
these MDCK cell lines were infected with an influenza virus.  As the newly produced virions 
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Figure 1.  Plasmid design and generation of MDCK cell lines bearing membrane-bound 
immunomodulators.  pcDNA3.1(+) plasmids containing immunomodulators anchored to the NA 
amino terminal (Type II transmembrane protein) and transmembrane domains or HA carboxyl 
terminal (Type I transmembrane protein) and transmembrane domains are stably transfected into 
MDCK cells.  Upon expression of the vector, the anchored immunomodulators are directed to 
lipid rafts at the cell membrane and expressed on the surface of the cell. 
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budded from the surface of the cell, they incorporated their normal HA and NA proteins along 
with NA- and HA-anchored immunomodulators.  The released virions were collected, purified 
and inactivated for use as whole virus vaccines (Fig. 2). 
This system improves adjuvant delivery in a significant way as tethering the cytokine to 
the antigen of interest keeps the adjuvant in close contact with the antigen ensuring that immune 
cells recruited by the adjuvant react with the antigen as well.  Tethering the immunomodulator 
also serves to extend the half-life in vivo, a factor that has been a limitation in previous cytokine 
protein-based immunotherapies (192).  Additionally, expressing the immunodulator construct in 
MDCK cells is cheaper and more efficient than producing and purifying recombinant proteins. 
Use of membrane-bound cytokines was first examined by others in tumor vaccine 
studies.  These groups found the membrane-bound versions of mammalian IL2, IL4, IL12 and 
GMCSF retained bioactivity and augmented immunity to tumor cell lines (211-214).  The use of 
membrane-bound immunomodulators as viral vaccine adjuvants were initially tested in a proof 
of concept study evaluating the use of a vaccine consisting of the human filamentous H3N2 
A/Udorn/72 bearing avian IL2 or GMCSF  in a chicken model (215).  This study found that IL2 
expressed on H3N2 retained IL2 activity in vitro and found vaccination with H3N2-IL2 led to 
elevated antiviral antibody levels in vivo when compared to H3N2 alone.  Additionally, the 
GMCSF expressed on H3N2 was found to be bioactive in vitro.  A second study examined this 
system in a mouse model using the murine H1N1 A/PR8/34 virions expressing murine IL2, IL4 
or GMCSF (216).  All three immunomodulators retained bioactivity when conjugated to H1N1 
in vitro and H1N1-IL2 and H1N1-IL4 protected from lethal challenge in mice. 
This dissertation work expands upon previous studies by making and characterizing new 
immunostimulatory constructs; avian IL4 and C3d (a breakdown product of the third component  
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Figure 2:  Generation of virions bearing membrane-bound immunomodulators.  After generation 
of stably transfected MDCK cell lines bearing membrane-bound immunomodulators, cells are 
infected with influenza virus.  As new virions assemble and bud from the surface of the cell, they 
incorporate their endogenous HA and NA surface proteins along with the HA or NA-anchored 
immunomodulator. 
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of complement) and testing these constructs and previously produced constructs (IL2 and GM-
CSF) expressed on LPAI H6N2. 
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Chapter 2 
Vaccine Adjuvant Selection, Design and Production 
H6N2:  A/Chick/California/2000-3 (H6N2) was selected for use in this study on the 
recommendation of the USDA (personal communication from D.E. Swayne, USDA, Southeast 
Poultry Research Laboratory, Athens, GA).  HPAI strains were eliminated from consideration as 
BSL-3 facilities were not available for use.  H6N2 is a LPAI that does not usually produce severe 
disease in chickens or other laboratory animals and is approved for use in BSL-2 facilities.  
Symptoms of H6N2 infection include reduced egg production, mild respiratory infection and 
yolk peritonitis (Yolk peritonitis occurs when eggs are not taken up by the oviduct but are 
deposited in the abdomen or by rupture of the oviduct.  Yolk material can spread over the 
abdominal organs leading to inflammation and bacterial infection) (217, 218).   
H6 viruses circulate in ducks and have been transmitted to chickens (20, 217).  In the 
United States, an outbreak of H6N2 occurred in 2000 in California totaling 12 incidents 
primarily involving layer-type birds with a lower number affecting backyard chickens and a 
broiler breeder (217).  Cases were detected in California again in 2001-2003 until a killed virus 
vaccine was deployed to eliminate the virus (20, 217).  Jackwood et al. have characterized H6N2 
infections in a laboratory setting (217).  Chicks were challenged with 1X10
6
 EID50 and 
monitored. Virus shedding was detected at high levels at 2 and 4 days with reduced titers at 7 
days.  Virus could consistently be recovered by oropharyngeal swabs but was less reliably 
recovered from cloacal swabs at all time points.   
Materials and Methods 
Generation of Cytokine-Bearing MDCK Cell Lines:  MDCK cells (ATCC) were 
trypsinized and grown to 80% confluence before transfection.   Three ug pcDNA3.1(+) plasmid 
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DNA (Invitrogen) containing GMCSF-HA, pcDNA3.1-NA-IL2, NA-FLAG-IL4 or NA-FLAG-
p29-p29-p29-p29-p29-p29 (p29x6) inserts were transfected using Lipofectamine2000 
(Invitrogen) as recommended in the manufacturer’s protocol in 6-well plates.  Transfectants were 
selected in growth media (DMEM, 10% fetal calf serum, penicillin, streptomycin and 
Fungizone) supplemented with geneticin (1.5mg/ml).  Stable transfectants were maintained in 
growth media containing 1mg/ml geneticin. 
Virus purification and inactivation:  Stable MDCK-immunomodulator cell lines were 
grown to 90-95% confluence in 100mm tissue culture-treated petri dishes in growth medium 
without geneticin.  Cells were washed with PBS with Ca
2+
 and Mg
2+
 and H6N2 was added to 
each petri dish at an MOI of 0.05.  Virus was adsorbed for 1hr and followed by the addition of 
DMEM with penicillin, streptomycin and 2ug/ml TPCK trypsin.  Viral supernatants were 
collected after 3 days.  Supernatants were pre-cleared by centrifugation at 5,000rpm (4,065.9 X 
g) for 20min in a GSA rotor (Sorvall).  Virus was concentrated by ultracentrifugation at 
22,100rpm (88,000 x g) for 1hr in a SW28 rotor (Beckman).  Concentrated virus was 
resuspended in PBS with Ca
2+
 and Mg
2+
.  For use as vaccine constructs, virus was inactivated by 
heating at 56C for 30min. 
Virus was quantified by hemagglutination assay.  100µl virus was added to the first well 
of each row and 50µl of PBS was added to each remaining well in the row of a V-shaped 96-well 
microtiter plate.  Serial dilutions were made by transferring 50µl from the first well of each row 
to each successive PBS-containing well.  50µl of a 0.5% chicken red blood cell (RBC) 
suspension was added to each well.  Plates were agitated and then incubated at room temperature 
until red blood cell controls settled.  The reciprocal of the last dilution where hemagglutination 
occurs was recorded as the viral titer in hemagglutinating units (HAU). 
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Vaccine Adjuvant Selection: 
GMCSF: Granulocyte macrophage colony-stimulating factor (GMCSF), also known as 
CSF2, is a member of the colony stimulating factor family.  GMCSF was initially defined by its 
ability to generate colonies of granulocytes and macrophages from bone marrow precursor cells 
in vitro and was later found to influence the behavior of mature myeloid cells (219-222).  
GMCSF is a secreted, glycosylated, single polypeptide chain produced by a variety of cells 
including fibroblasts, endothelial cells, macrophages, smooth muscle cells and osteoblasts upon 
stimulation from inflammatory factors corresponding to infection such as IL-1, TNF and LPS 
(219, 223).  Activation of the GMCSF receptor CSF2R activates the JAK–STAT, MAPK and 
PI3K pathways (219, 224).  GMCSF is polyfunctional and increases the survival, proliferation, 
differentiation and activation of monocytes, macrophages, neutrophils, eosinophils and basophils 
and can be used to generate dendritic cell populations (219).   
GMCSF has been tested as a therapeutic in many studies.  GMCSF (trade name 
Leukine®, generic name Sargramostim) has been safely used for many years to boost leukocyte 
levels in immunosuppressed patients and has been shown to decrease infectious complications in 
those undergoing chemotherapy (94, 225, 226).  Numerous groups have incorporated GMCSF 
into anti-tumor vaccines with varying results (227).  In general, when administered in low doses 
(up to 80ug) for limited periods of time, GMCSF can increase vaccine-induced immune 
responses and synergize with other adjuvants including MPL, alum and other cytokines while 
higher doses of GMCSF (100-500ug) tends to suppresses immune responses (227, 228).  
Immune suppression seen with larger doses of GMCSF is thought to be due to the attraction and 
proliferation of myeloid suppressor cells, the rapid recruitment of macrophages leading to quick 
vector clearance or an increase in proapoptotic signaling in CD8+ T cells (228-232). 
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GMCSF has been tested as an adjuvant for several infectious disease vaccines, primarily 
as a component of recombinant DNA vaccines.  As with tumor vaccines, GMCSF could be either 
protective or suppressive depending on the immunogen, timing, dosage, vaccine vector and route 
of administration (233).  Several groups have found that GMCSF adjuvantation of experimental 
DNA vaccines using plasmid or viral vectors led to enhanced immune responses and or 
protection to pathogens including Clostridium botulinum (234), hepatitis B (235-237), Japanese 
encephalitis virus (238), porcine reproductive and respiratory syndrome virus (PRRV) (239), 
SIV (240, 241), HIV (242), pseudorabies (243) and haemonchus contortus (244).  In a protein-
based HIV vaccine, Ahlers et al. found that adjuvanting with 2-5ug recombinant GMCSF 
enhanced both cellular and humoral immune responses (245).   
Previous studies by others relating to GMCSF adjuvantation and intranasal vaccination, 
mucosal immunity, chicken models and influenza are of particular pertinence to this study.  
Okada et al. tested three doses of an intranasally delivered HIV DNA vaccine containing 2ug 
HIV DNA, 2ug plasmid GMCSF and liposomes in mice and found increased anti-HIV serum 
IgG levels, and fecal IgA levels in comparison to antigen and liposomes alone (246).  Bradney et 
al. vaccinated mice mucosally with 4 doses of 4ug GMCSF and 10ug HIV peptide and observed 
IgG levels comparable to those induced by a cholera toxin adjuvant (247).  Ramsburg et al. used 
a single dose of VSV vector expressing GMCSF and found increased CD8+ T cells and 
increased protection from challenge (248).  In a similar model Parker et al. used an attenuated 
HSV-1 viral vector expressing GMCSF and this increased protection from challenge (249).  
Also, Nambiar et al. noted reduced bacterial loads after mycobacterium challenge following 
vaccination with BCG expressing GMCSF (250). 
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Two studies have been conducted in chickens using chicken GMCSF as an adjuvant for 
infectious bronchitis virus (IBV).  Tan et al. vaccinated chickens intramuscularly with 2 doses of 
150ug plasmid GMCSF plus 150ug of IBV plasmid DNA and found significantly enhanced 
cellular and humoral immune responses plus increased protection compared to IBV plasmid 
DNA alone (251).  Zeshan et al. vaccinated chickens in ovo with 10
8
 TCID50 of an adenovirus 
vector carrying GMCSF and IBV antigen and observed increased IBV specific antibodies (252).  
In addition they found increased spleen cell proliferation and IFN-γ with limited IL-4 production 
indicating the enhancement of cell-mediated immune responses.  Furthermore, following 
challenge 100% of birds vaccinated with IBV and the GMCSF adjuvant were protected from 
lesions compared to 70% of those vaccinated with IBV alone.  These results indicate that 
GMCSF can be an effective adjuvant in chickens. 
In a series of studies Babai et al. encapsulated H3 and N2 from A/Shangdong/9/93 with 
GMCSF and or IL2 in liposomes and vaccinated mice and found higher antibody titers, increased 
survival rates and protection for over 1 year (253-255).  Orson et al. delivered a series of 4-5ug 
of plasmid DNA containing H1 from A/PR8/34, GMCSF and IL12 and observed increased 
protection levels and the generation of neutralizing cross-protective antibodies (256).  Loudon et 
al. vaccinated macaques 3 times with 1.8ug plasmid encoding H1 from A/New Calendonia/20/99 
and 0.2ug of plasmids encoding GMCSF with each dose being delivered intradermally via gene 
gun (257).  They found significantly increased levels of hemagglutination inhibiting (HI) 
antibodies and cytokine-secreting HA-specific T cells in the periphery of macaques and 
influenza A-specific mucosal antibodies and T cells in the lung and gut-associated lymphoid 
tissues.  Ramanthan et al. conducted a randomized trial in human cancer patients where 250ug of 
recombinant GMCSF was administered with seasonal influenza vaccines (258).  They did not 
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find any enhancement of response to influenza vaccines; however the 250ug dose of GMCSF is 
in the 100-500ug range that is now understood to be suppressive. 
These studies showing efficacy of adjuvanting vaccines with GMCSF in different 
delivery methods and in chickens plus its ability to enhance responses to influenza made it an 
attractive candidate for study in our model.  Previous results from this laboratory demonstrated 
that chicken GMCSF anchored to murine A/PR8/34 retained biological activity and could 
stimulate the proliferation of bone marrow cells (215).  We hypothesized that chicken GMCSF 
would act in a similar manner when anchored to an avian strain and enhance the immunogenicity 
of H6N2. 
Materials and Methods: 
GMCSF-HA plasmid design and construction:  Chicken GMCSF was fused to the 
transmembrane domain of the influenza HA as described previously (215).   Briefly, full length 
GMCSF was synthesized using 6 oligonucleotides (each approximately 80-100bp including 25bp 
overhangs) that spanned the entire coding region (GenBank # NM_001007078.1) under 
conditions described by Dillon and Rosen (259).  5’ HindIII and 3’ BamHI restriction sites were 
added to the ends of the full length GMCSF by PCR using the following primers: forward 5′-
GCATAAGCTTCCACGATGCTGGCCCAGCTC-3′ and reverse 
 5′-GCATGGATCCTTAGATGCAGTCTTT CTCCT-3′.  The sequence was ligated into 
pcDNA3.1(+).  A 70 amino acid segment of HA derived from the influenza virus A/WSN/33 
containing the carboxy-terminal, cytoplasmic tail, transmembrane region and 26 amino acids of 
the stalk region containing 5’ BamHI and 3’ EcoRI restriction sites was amplified using the 
following primers: forward 5′-CCGGATCCAATGGGACTTATGATTATCC-3′ and reverse  
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5′-CCGAATTCTCAGATGCATATTCTGCACTGC-3′.  The HA sequence was ligated into 
pcDNA3.1-GMCSF creating pcDNA3.1-GMCSF-HA  
 Bioassay for chicken GMCSF:  The bioassays for chicken granulocyte macrophage 
colony stimulating factor (GMCSF) were performed as previously described (215).  Briefly, 
bone marrow was flushed from the femur of an exsanguinated market chicken (Chase Road 
Poultry) with Iscove’s medium, washed three times and resuspended in Iscove’s supplemented 
with 5% fetal calf serum, 2% autologous chicken serum, 2mM L-glutamine, 1mM pyruvate and 
penicillin, streptomycin and fungizone.  3X10
5
 cells/150µl were added to 96 well plates 
containing dilutions of GMCSF-containing COS7 supernatants, heat inactivated H6N2 or H6N2-
GMCSF.  Plates were incubated at 40C for 72hrs with the addition of 1µCi of [3H] thymidine for 
the last 18 hours.   
 Results:  GMCSF stimulated the proliferation of bone marrow cells.  To confirm that 
HA-anchored GMCSF was expressed on H6N2 virions and retained bioactivity, heat-inactivated 
H6N2-GMCSF was incubated with chicken bone marrow cells for 72 hours in a thymidine-
uptake proliferation assay (Fig. 3).  Incubation of bone marrow cells with a COS7 supernatant 
containing soluble GMCSF increased thymidine uptake in comparison to untreated cells.  
Incubation with 400HAU H6N2-GMCSF resulted in an increase in thymidine uptake while 
incubation with H6N2 was unable to induce a similar increase in proliferation.  The ability of 
H6N2-GMCSF to induce the proliferation of bone marrow cells indicated that GMCSF is 
expressed on the surface of the virion, retained bioactivity in the anchored-confirmation and was 
not inactivated by viral inhibition steps.  
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Figure 3.  Bioassay for GMCSF activity.  Dilutions of soluble GMCSF (light gray bars), H6N2 
(dark gray bars) and H6N2-GMCSF (black bars) were incubated with chicken bone marrow cells 
for 72hrs.  White bars (bone marrow cells alone) show normal cell proliferation.   
3
H-thymidine 
was added for the last 18hrs.  Samples were tested in triplicate and cell proliferation was 
measured by uptake of radio-labeled thymidine in counts per minute (Representative assay). 
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 IL2:  The cytokine interleukin 2 (IL2) influences the homeostasis, differentiation and 
behavior of many lymphocyte subtypes.  Under steady-state conditions, IL2 is primarily 
produced by CD4+ T helper cells in secondary lymphoid organs (260-262).  IL2 is produced at 
lower levels by CD8+ T cells, natural killer cells (NK) and natural killer T cells (NKT), dendritic 
cells and mast cells (260, 263, 264).  IL2 signals through the high-affinity trimeric IL2 receptor 
(IL2R) or the lower-affinity dimeric IL2R (260).  Cells expressing high levels of dimeric IL2R 
such as naïve CD8+ T cells, memory CD4+ T cells, memory CD8+ T cells and NK cells are 
sensitive to exogenous IL2 but typically not responsive to low physiological levels of IL2 found 
during steady-state conditions (260, 265).  After receptor engagement, signal transduction occurs 
through the JAK-STAT, PI3K-AKT and MAPK pathways and the IL2-IL2R complex is 
internalized (260, 261, 266, 267). 
IL2 signaling impacts CD8+ T cells in all phases of the immune response (primary 
expansion, contraction, memory cell production and secondary expansion) (260).  After acute 
infection, IL2 levels increase rapidly in the secondary lymphoid organs activating and driving the 
proliferation of naïve antigen-specific CD8+ T cells (260).  Antigen-specific CD8+ T cells that 
do not receive strong IL2 signals show weakened primary and secondary expansion and 
insufficient IL2 signals leading to reduced long-lived CD8+ memory T cell production (260). 
IL2 significantly influences the differentiation of CD4+ T cells and their polarization into 
Th1 or Th2 cells.  IL2 enhances Th1 cell proliferation by the induction of T-bet expression and 
an increase in the IL12Rβ2 subunit (260).  IL12 signaling leads to the production of Th1 
transcription factors and IFNγ, which is enhanced by IL2 produced by responding T cells (260, 
268).  In Th2 cells, IL2 induces early expression of IL4Rα (260). 
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IL2 was selected as an adjuvant for this study due to this laboratory’s extensive 
experience in the cloning and characterization of avian IL2 and the success of other groups using  
avian IL2 as a vaccine adjuvant (269, 270).  Hulse and Romero and Li et al. found chicken IL2 
administered as a recombinant protein or plasmid DNA was able to enhance antibody responses 
and increased protection to infectious bursal disease virus (IBDV) (271, 272).  Tarpey et al. 
coadministered a Marek’s disease vaccine vector encoding chicken IL2 with IBDV and 
infectious bronchitis disease vaccines and saw enhanced protection to each vaccine (273).  Zhou 
et al. found intramuscular injection of geese with 300-350ng soluble goose IL-2 plus an 
inactivated oil-adjuvanted whole-virus H5N2 influenza vaccine enhanced HI antibody titers 
(274).   Xiaowen et al. vaccinated newly hatched chicks intranasally with inactivated whole-virus 
H5N2 and 50ug recombinant IL2 and observed increased IgA and IgG secreting cells in the 
respiratory tract (275).   
Membrane-bound IL2 has been tested as an influenza vaccine adjuvant by Herbert et al. 
in a mouse model and by Yang et al. in a chicken model.  Herbert et al. vaccinated mice 
subcutaneously with 0.375ug β-propiolactone inactivated H1N1 A/PR/8/34 bearing murine IL2 
(H1N1-IL2) and challenged with a lethal dose (1000 TCID50) of H1N1 (216).  In comparison to 
mice vaccinated with H1N1 alone, H1N1-IL2 vaccinated mice had significantly lower viral loads 
in lungs and significantly enhanced survival.  Furthermore, mice exhibited a favorable 
IgG2a:IgG1 response, indicative of Th1 skewing. 
Yang et al. vaccinated chicks subcutaneously with 10ug H3N2 A/Udorn/72 bearing NA 
anchored IL2 (H3N2-IL2) at 1 week and boosted with the same dose at 4 weeks (215).  After 
booster vaccination, serum ELISA assays demonstrated chicks vaccinated with H3N2-IL2 had 
significantly (p < 0.05) higher antiviral titers than those vaccinated with H3N2 alone.  HI assays 
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indicated that 100% of chicks vaccinated with H3N2-IL2 had titers of 20 or more while only 
42.8% of those vaccinated with H3N2 reached the same threshold (χ2 value of p = 0.018).   
We hypothesize IL2 anchored to H6N2 will behave similarly to the membrane-bound IL2 
in Herbert et al. and Yang et al.  
Materials and Methods: 
NA-IL2 Plasmid Design and Construction:  A 51 amino acid region containing the full 
amino-terminal cytosolic and transmembrane domains and 17 amino acids of the stalk domain 
were derived from the NA segment human H1N1 influenza A/WSN/33 segment (Genbank 
L25817) and fused to the full length coding sequence of mature chicken IL2 using PCR based 
cloning techniques described previously (215).  The following primer pairs and restriction 
endonuclease sites were used (restriction sites underlined): NA forward 5’ 
GACTGGATCCCTGCCATGAATCCAAAC 3’ (BamHI), NA reverse 5’ 
ACTGCCTTGGTTGCATAT 3’ (StyI), IL2 Forward 5’ GCATCCAAGGCGCATCTCTATCA 
3’(StyI), and IL2 reverse primer 5’ GCTAGAATTCTTATTTTTGCA 3’ (EcoRI).  The NA-IL2 
coding sequence was ligated into the plasmid pcDNA3.1(+) (Invitrogen) creating pcDNA3.1-
NA-IL2. 
Bioassay for chicken IL2:  The bioassays for chicken IL2 activity were performed as 
previously described (215, 276).   Briefly, spleens were removed from market chickens, passed 
through stainless steel mesh, washed three times in Iscove’s medium (Gibco) and cultured at 107 
cells/ml in Iscove’s medium with bovine serum albumin (BSA), 2mg/mL, Concanavalin A 
(ConA),10µg/mL, and penicillin, streptomycin and fungizone at 40°C.  At 24hrs ConA was 
neutralized with 0.05 M α-methyl mannopyrannoside, the media diluted 2-fold and supplemented 
with autologous serum (final concentration of 2%) and incubated for 2 additional days.  Viable 
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chicken T-cell blasts were isolated following separation on Histopaque, washed, counted, and 
used as indicator cells.  To assay the bioactivity of IL-2 expressed on H6N2 virions, 400, 200 
and 100 HAU of H6N2-IL2 and H6N2 viral particles were added to 96 well round bottom plates 
and chicken T-cell blasts were added at 5 X 10
4 cells/well in Iscove’s medium supplemented 
with 2% autologous chicken serum, 2 mg/mL bovine serum albumin, penicillin, streptomycin 
and fungizone.  Recombinant chicken IL2 was added at a concentration of 10
-10
 M as a positive 
control.  Cultures were incubated overnight at 40C in 5% CO2, the last 6h with 1 µCi of [3H] 
thymidine. Cells were harvested on glass fiber filters using an automated harvester and counted 
in a LKB Betaplate Β-counter.  Controls included blast cells alone and blast cells stimulated with 
soluble recombinant IL2. 
Results:  IL2 is a potent stimulator of T cell growth.  To confirm NA-IL2 anchored to 
H6N2 retained bioactivity as it did in Yang et al. and Herbert et al., it was tested in a T cell 
proliferation assay (Fig. 4).   Recombinant soluble IL2 served as a positive control and it 
stimulated thymidine uptake about 8 fold.  400HAU H6N2-IL2 also stimulated T cell blasts, 
while 400HAU of wild-type H6N2 moderately inhibited T cell proliferation.  These results 
indicate NA-anchored IL2 was expressed on inactivated H6N2 virions and retained its 
bioactivity. 
C3d:   The complement system is part of the innate immune system and consists of more 
than 30 proteins, which exist as zymogens, present in plasma and on cell surfaces (277, 278).  
Complement plays three major physiologic roles: 1) Acts as a host defense against infection by 
the opsonization of pathogens, chemotaxis and activation of leukocytes and lysis of bacteria and 
infected cells, 2) Serves as a bridge between the innate and adaptive immune system by  
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Figure 4.  Bioassay for IL2 activity.  Dilutions of recombinant IL2 (light grey bars), H6N2 (dark 
gray bars) and H6N2-IL2 (black bars) were incubated with chicken T cell blasts overnight.  
White bars (T-cell blasts) show normal cell proliferation.   
3
H-thymidine was added for the last 
6hrs.  Samples were tested in triplicate and cell proliferation was measured by uptake of radio-
labeled thymidine in counts per minute (Representative assay). 
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augmentation of antibody responses and enhancement of immunologic memory and 3) Disposes 
of waste by clearing immune complexes and apoptotic cells (279).  The complement cascade can 
be activated through three separate mechanisms, the classical, lectin, and alternative pathways.  
The classical pathway responds to IgM- and IgG-tagged immune complexes, Apoptotic cells, 
certain viruses and gram-negative bacteria and ligands bound to C-reactive protein (277).  The 
lectin pathway is triggered when the pattern-recognition molecule mannose-binding lectins binds 
to terminal mannose groups found on many types of bacteria.  The alternative pathway is 
initiated by the spontaneous hydrolysis of C3 and after contact with multiple types of bacteria, 
fungi, viruses and tumor cells (277, 278).   The end products of these pathways, either C4bC2a 
or C3bBb, react with the C3 convertases and trigger the remainder of the complement pathway 
(278).  C3 is hydrolyzed into C3b, then converted by Factors I and H to ic3b and then to C3c and 
C3d by Factor I and CR1 (278).   
 The C3 degradation factor C3d is an opsonizing agent that binds foreign antigen and 
complement receptor 2 (CR2, CD21) (280, 281).  CR2 is found on B cells, follicular dendritic 
cells (FDCs) and a subset T cells and serves as a link between the innate and adaptive immune 
systems (282).  FDCs are present in the germinal center of lymph nodes and have a critical role 
in antigen presentation (283).  CR2 on FDCs binds antigens coated with C3d and retain these 
antigens for extended periods of time enhancing antigen presentation (278, 284, 285).  In 
addition, this trapping of opsonized antigen is important for the production of high-affinity 
antibodies and generating and maintaining memory B cells (282, 286, 287).  CR2 is also part of 
the B-cell antigen receptor complex that also includes CD19 and CD81 (278).  B cells are 
normally activated when antigen binds to the B-cell recptor, surface IgM, Igα or Igβ (BCR) (278, 
288).  When antigen is linked to C3d, the CR2/CD19/CD81 complex is engaged along with the 
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BCR resulting in cross-talk between pathways and enhanced cell activation (278, 288, 289).  The 
dual signaling of these receptor complexes has a strong molecular adjuvant effect and can lower 
the threshold of antigen needed for B-cell activation 10,000-fold, counter inhibitory signals and 
reduce apoptosis (288-290).  Other effects of the crosslinking of the BCR and CR2 include 
enhanced antigen uptake and improved presentation by MHCII molecules (291, 292) 
The ability of C3d to link the innate and adaptive immune responses, lower antigen 
threshold, improve antigen presentation and enhance phagocytosis suggests that it would serve as 
an excellent adjuvant.  The first study utilizing C3d as an adjuvant was done in 1996 by 
Dempsey et al. (290).  Mice were immunized with recombinant hen egg lysozyme (HEL) fused 
to two or three copies of full-length murine C3d.  The HEL-C3d fusion constructs were found to 
be 1,000-10,000-fold more immunogenic than HEL alone.  In the time since then, human, 
chicken, bovine and porcine C3ds have been cloned and tested as adjuvants (293-296).  
Additionally many methods have been developed to link C3d repeats (typically 3 copies (C3d3)) 
to antigenic proteins by plasmid DNA gene fusions, covalently, by biotinylation, the baculovirus 
expression vector system and immune-stimulating complexes (ISCOMs) (100, 294, 297-299).  
Numerous C3d3-antigen vaccine constructs have been tested in murine models and many have 
displayed increased immunogenicity when compared to vaccination with antigen alone including 
HIV ENV and gp120, influenza HA and M2, measles HA, bovine viral diarrhea virus E2, 
Hepatitis E HEV-p179, pseudorabies virus gC, Rift Valley Fever virus Gn, Bacillus anthracis 
PA and Streptococcus pneumonia capsular polysaccharide (298, 300-314).  
Bower and Ross (315) found that the 28 amino acid segment of C3d that binds the CR2 
receptor (P28) is sufficient for adjuvant activity.  In that study they found that 4 repeats of 
murine P28 conjugated to the N-terminus of HIV gp120 elicited enhanced cellular and humoral 
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immune responses that were statistically similar to those generated by linking 3 copies of full 
length C3d to gp120.  This further indicated that C3d adjuvant activity acts through the CR2 
receptor and also confirmed that a smaller adjuvant fragment may be used.  Other groups have 
successfully tested murine P28 as an adjuvant for PRRV, West Nile virus, foot-and-mouth 
disease virus and Plasmodium berghei (296, 316-318).  These groups found 4 to 6 repeats of P28 
conjugated to antigens resulted in the strongest immune responses. Additionally, Liu and Niu 
(295) found the 29 amino acid chicken CR2 binding domain of C3d (P29) enhanced immune 
responses to Newcastle disease virus when conjugated to NDV-F protein, with the highest 
responses coming when 6 copies of p29 (p29x6) were used.   
Of particular relevance to this study are the previous studies done with C3d and influenza 
antigens.  Ross et al. (297) generated a DNA vaccine encoding 3 copies of murine C3d to the 
secreted form of HA from the murine influenza strain A/PR/8/34 (H1N1) (sHA-mC3d3) that was 
administered by gene gun to BALB/c mice.  They found sHA-mC3d3 DNA accelerated avidity 
maturation of antibodies to HA and the appearance of hemagglutinin- inhibition activity.  These 
quicker responses also correlated with earlier appearances of protective immunity.  Additionally, 
complete protection from live virus challenge could be achieved by a single vaccination with 
sHA-3C3d DNA than with a non-adjuvanted form of HA DNA.  In a later study Mitchell et al. 
(305) found that sHA-mC3d3 could induce heterosubtypic immunity.  BALB/c mice were 
vaccinated with plasmids containing 3 copies of C3d and the HA from A/Puerto Rico/8/34 
(H1N1) or A/Aichi/2/68-x31 (H3N2) by gene gun.  While sera from the vaccinated mice did not 
neutralize the heterologous virus, the mice were protected from heterosubtypic challenge with a 
lethal dose of virus.  Li et al. (307) tested a DNA vaccine in mice containing a plasmid 
expressing C3d as above and the equivalent sHA region of the swine influenza 
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A/Swine/Guangdong/164/06 (H3N2).  In contrast to the previous studies, BALB/c mice were 
vaccinated intramuscularly.  The vaccinated mice were challenged with either 
A/Swine/Heilongjiang/74/2000 (H3N2) or A/Swine/Guangdong/96/06 (H1N1).  Antibody titers 
and affinity resulting from immunization with sHA-mC3d3 were higher and stronger than those 
vaccinated with HA alone.  One week after challenge with H3N2, no virus was isolated from the 
mice immunized with any of the HA expressing plasmids.  In mice challenged with heterologous 
H1N1, only mice immunized with sHA-mC3d3 did not show lesions in the kidneys or brain, 
again due to increased antibodies and stronger affinity maturation. 
C3d has also been tested as an adjuvant in recombinant-protein influenza vaccines.  
Watanabe et al. (306) tested C3d as an alternative to cholera toxin B (CTB) or lymphotoxin (LT) 
for the induction of mucosal immunity.  Intranasal vaccination of BALB/c mice with the 
recombinant protein sHA-mC3d3 resulted in locally secreted IgA and serum IgG antibodies and 
led to complete protection against homologous virus challenge while sHA alone was unable to 
do so.  Zhang et al. (318) fused 2 copies of chicken C3d to the matrix protein M2 gene of 
A/chicken/Guangdong/2000 (H9N2).  While the sequence of M2 is highly conserved amongst a 
wide variety of avian influenza viruses and expressed on infected cells, it is weakly 
immunogenic and is present in limited numbers on virus particles (318).  This group hoped C3d 
would boost the immunogenicity of M2 as it did for HA in the aforementioned studies.  They 
found anti-sM2 antibody was elevated in chickens intramuscularly vaccinated with the C3d 
adjuvant, however, protection ratios only reached 13.3% and further studies were not pursued. 
The previous studies suggest that C3d has great promise as a membrane-bound adjuvant 
due to its ability to 1) enhance humoral and mucosal immune responses to HA 2) increase 
survival and induce heterosubtypic immunity in mice and 3) act effictively when delivered 
56 
 
 
 
subcutaneously or intranasally.  While the chicken p29x6 construct has not been tested with 
influenza, its efficacy in NDV vaccines in chickens suggests potential use as an adjuvant for 
other chicken vaccines.  Although C3d adjuvanted M2 did not result in acceptable protection 
levels in chickens, its use as an adjuvant offers advantages over the system utilized by Zhang et 
al. (318).  First, only 2 copies of C3d were conjugated to M2 which may not be sufficient for 
increasing immunogenicity.   The other previously mentioned studies found 3 copies of C3d to 
be effective while Liu et al. (295) found 6 repeats of the CR2 binding domain elicited the 
strongest responses.  Additionally, attaching p29 to the whole virion allows its adjuvant effects to 
act on all viral proteins, including the highly immunogenic HA and NA along with M2 and the 
remaining internal proteins allowing for the possibility of immune responses to a wider range of 
antigens and the increased potential for heterosubtypic protection. 
Materials and Methods: 
NA-p29x6 Plasmid Design and Construction:  Hexamers of the 29 amino acid CR2-
recpetor binding sequence of chicken C3d (p29) were generated using a protocol modified from 
Liu and Niu (295).  The sequence of p29 containing 5’ HindIII and BamHI restriction sites and a 
3’ BglII restriction site, FLAG tag and a KpnI restriction site was generated in 2 PCR reactions 
using overlapping oligonucleotides.  The initial PCR reaction used the following two primers 
with 25 base pair overlaps:   forward 5’-
AAGCTTGGATCCAAAGTCCTGATGAGTTCTCCAAAGATGGCACCCACTGGGCGGAA
CGCAACGCCCACACCTACAACATCG-3’ and reverse 5’-
GGTACCTTACTTGTCATCGTCGTCCTTGTAGTCAGATCTAGCGTAGGACGTCCCCTCG
ATGTTGTAGGTGTGGGCGTTGCG-3’.  The PCR product was gel purified using the Wizard 
SV Gel and PCR Clean-Up System (Promega) and reamplified with the following primers:  
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forward 5’-GCATAAGCTTGGATCCAAAGTCCTG-3’ and reverse 5’-
GTCAGGTACCTTACTTGTCATCGTC-3’.  The sequence was digested with HindIII and KpnI 
and inserted into puc19 (Invitrogen).  2 aliquots of puc19-p29-FLAG were made.  The first was 
cut with BglII and EcoRI and the large fragment containing the puc19 backbone and p29 minus 
the FLAG tag and stop codon was recovered.  The second was cut with BamHI and EcoRI and 
the small fragment containing p29 with FLAG and the stop codon were recovered.  The two 
fragments were ligated together (BamHI and BglII cut sites can be ligated together and then 
cannot be cut again by either enzyme) yielding puc19-p29-p29-FLAG.  2 aliquots of the puc19-
p29x2-FLAG plasmid were digested with BglII and EcoRI or BamHI and EcoRI.  The fragments 
recovered from these digests, the large segment from BglII/EcoRI containing the p19 backbone 
and 2 copies of p29 and the small segment from BamHI and EcoRI containing 2 copies of p29, 
the FLAG tag and stop codon were ligated together to make puc19-p29x4-FLAG.  The 4x repeat 
of p29 was cut from the plasmid with BglII and EcoRI and ligated into the puc19-p29x2-FLAG 
plasmid to create puc19-p29X6-FLAG.  The FLAG-tagged p29X6 repeat was cut from the 
plasmid using BamHI and EcoRI and ligated into pcDNA3.1-NA (Derived by excising IL2 with 
BamHI and EcoRI from pcDNA3.1-NA-IL2) to create pcDNA3.1-NA-p29x6-FLAG. 
Immunofluorescence Detection of p29x6 on MDCK Cells:  1X10
5
 MDCK and 
MDCK-p29X6 cells were adhered to coverslips in 24 well plates.  Cells were fixed with 4% 
paraformaldehyde in PBS for 15 min at room temperature and washed with PBS.  Coverslips 
were blocked with 10% BSA in PBS for 30min at 37C then incubated with mouse anti-FLAG 
primary antibody (Sigma) at a 1:100 dilution in 3% BSA.  After washing, coverslips were 
incubated with a 1:500 dilution of FITC conjugated goat anti-mouse secondary antibody 
(Anaspec) for 45 min. in the dark at 37C.  Coverslips were covered with a small drop of Slow 
58 
 
 
 
Fade Gold® Reagent with DAPI (Invitrogen) and mounted to microscope slides.  Images were 
acquired using a Nikon E600 microscope with epifluorescence at 40X magnification. 
ELISA for Detection of p29x6 on H6N2 Virions:  H6N2 and H6N2-p29x6 were diluted 
to 100HAU/100µl or 10HAU/100µl and adsorbed to 96-well ELISA plates (Immulon II, 
Dynatech Laboratories Inc.) overnight at 4C.  Coated wells were then blocked (2% BSA in 
PBST) overnight at 4C.  After washing, wells were incubated with mouse anti-FLAG IgG 
(1:1000; Sigma) in blocking buffer overnight at 4C.  Following washing wells were incubated 
with alkaline phosphatase-conjugated goat anti-mouse IgG (1:2000; Sigma) for 3hrs at 25C.  
Wells were washed and incubated with 200µl p-Nitrophenyl phosphate (pNPP; Sigma) in the 
dark for 30min at room temperature. The reaction was halted by the addition of 50µl 3 N NaOH 
and absorbance for the stopped was read at 405 nm using a BioTek Epoch microplate 
spectrophotometer. 
Results:  To ensure p29x6 was expressed on MDCK cells and H6N2 virions 
immunofluorescence and ELISA assays were conducted.  To detect the presence of FLAG-
labeled p29x6 on the surface of MDCK cells, cells were grown on coverslips and stained with an 
anti-FLAG primary antibody and a FITC-labeled secondary antibody (Fig. 5).  No wild type 
MDCK cells were found to be FITC positive while a majority of MDCK-p29x6 cells were 
stained indicating that p29x6 is expressed on H6N2-p29x6.  Clusters of p29x6 were seen near the 
outer edges of many cells possibly indicating concentration at lipid rafts.  
To detect the presence of FLAG labeled p29x6 on H6N2 virions, H6N2 and H6N2-p29x6 
were coated on ELISA plates and stained with anti-FLAG primary antibody and alkaline 
phosphatase-conjugated secondary antibody (Fig. 6).  Alkaline phosphatase activity was elevated  
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Figure 5.  Immunofluorescence labeling of MDCK cell lines expressing NA-p29x6.  Left panel: 
Wild type MDCK.  Right panel: MDCK-p29X6.   Green = FITC positive for p29x6 expression.  
Blue = DAPI counterstained nuclei. 
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Figure 6.  ELISA for detection of p29x6 on H6N2 virions.  Wild type H6N2 (gray bars) and 
H6N2-p29x6 (black bars) were labeled with anti-FLAG primary antibodies and alkaline 
phosphatase-conjugate secondary antibodies.  Alkaline phosphatase activity was measured by the 
addition of pNPP and absorbance at 405nm.  Samples were tested in triplicate and SEM was 
calculated. 
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at both 100HAU and 10HAU dilutions of H6N2-p29x6 in comparison to wild type 
H6N2indicating that p29x6 is expressed on inactivated H6N2 virions.  The similar absorbance 
measurements for both 100HAU and 10HAU are likely due to saturation of the available sites on 
the microtiter plate at the lower concentration.   
IL4: Interleukin 4 is a pleiotropic type II cytokine produced primarily by CD4+ Th2 cells 
and to a lesser extent by basophils, mast cells, NK1.1 T cells and eosinophils (319-323).  IL4 
drives the differentiation of antigen-stimulated naïve T cells from Th0 cells into Th2 cells 
leading to the production of IL5, IL10 and IL13 while suppressing Th1 cell responses (319, 324, 
325).  IL4 also controls facets of immunoglobulin class switching, determining if human B cells 
switch to IgE and IgG4 production or if murine B cells shift to IgE and IgG1 (319).  IL4 plays 
prominent roles in the development of protective responses to hemlminths and extracellular 
parasites (319, 326).  IL-4 also plays a role in macrophage activation (327).  Additionally, IL4 
serves as a B cell growth factor, increases expression of MHC class II molecules in B cells, 
increases expression of CD23, upregulates production of the IL-4 receptor and stimulates 
changes in the vascular endothelium to favor recruitment of T cells and eosinophils (319). 
While endogenous IL4 drives a Th2 response that is unfavorable for mounting an 
immune response to influenza vaccines, as an adjuvant it has displayed surprising behaviors.  
Biedermann et al. found co-delivering IL4 with Leishmania major enhanced IL12 production 
and Th1 responses (328).  Eguchi et al. demonstrated similar results in a transfected tumor 
vaccine (329).  Most importantly, when Herbert et al. vaccinated mice with H1N1-IL4, mouse 
serum antibody IgG1:IgG2a ratios were indicative of a Th1 immune response (216).  
Furthermore, of all of the constructs tested in their study, mice vaccinated with membrane-bound 
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IL4 adjuvanted vaccines has the lowest average lung viral titers and highest rate of survival.  
These results made IL4 an obvious candidate for this study. 
It should be noted that concerns have been raised over use of IL4 as an adjuvant.  In 
2001, Jackson et al. found that a mousepox virus (ectromelia) expressing IL4 was able to 
overcome genetic resistance and was also able to infect previously vaccinated mice resulting in 
acute disease with high mortality.  This led to concerns that mutant human poxviruses (such as 
smallpox) resistant to vaccination could be produced by the inclusion of IL4.  The generation of 
a higher virulence influenza virus is highly unlikely to result from our study for a number of 
reasons.  As described above, IL4 adjuvantation increased efficacy of a killed H1N1 murine 
vaccine.  Additionally, our vaccine particles do not actively synthesize IL4 reducing the risk of 
complications that could potentially arise due to excessive expression of the cytokine.  
Furthermore, poxviruses are highly reliant on Th1 mechanisms for clearance (Th1 responses 
were hampered by IL4 in Jackson et al.) while Th1 or Th2 responses can clear influenza as seen 
with current seasonal influenza vaccines. 
Materials and Methods:   
NA-IL4 Plasmid Design and Construction:  Chicken IL4 was fused to the 
transmembrane NA segment previously described in the NA-IL2 plasmid design section.  Mature 
IL4, excluding the IL4 signal sequence was amplified by PCR from pCI-neo-IL4 (a gift from P. 
Kaiser).  5’ StyI and 3’ EcoRI restriction sites were added using the following primers:  forward 
5’-GATCCCTTGGCCTGTGCTTACAGCTCTCAGT-3” and reverse  
5’-GATCGAATTCTCACTTATTTTTAGCTAGTT-3’.  A FLAG sequence was added to the 3’ 
end of IL4 using the previously described forward primer and the reverse primer  
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5’-GATCGAATTCTCATTTGTCGTCGTCGTCTTTATAGTC-3’.  The IL4-FLAG sequence 
was ligated into pcDNA3.1-NA creating pcDNA3.1-NA-IL4-FLAG. 
Bioassay for IL4 activity:  IL4 activity was measured by its ability to stimulate nitric 
oxide (NO) production in macrophages as described by He et al. (330).  HD11 chicken 
macrophages (A gift from H. He, USDA, College Station, TX) were maintained in DMEM 
supplemented with 10% chicken serum, penicillin, streptomycin, fungizone, and 1.5 mM L-
glutamine at 39 °C.  100µl aliquots of cell suspension (2 × 10
6
 cells/ml) were seeded into each 
well of a round-bottom 96-well plate and allowed to grow to about 85% confluence.  Before 
stimulation, cells were replaced with fresh medium containing no phenol red.  Cells were 
stimulated with or without 64, 125, 250, 1000 and 1500 HAU H6N2, H6N2-NA-IL4 and H6N2-
IL4-HA overnight.  NO levels were measured using its stable metabolite, nitrite using the Griess 
assay (Promega).  Briefly, 100 μl culture supernatant from each well was transferred to the wells 
of a flat-bottom 96-well ELISA plate and combined with 50μl of 1% sulfanilamide and 50μl of 
0.1% naphthylenediamine.  After 10 min incubation at room temperature, the nitrite 
concentration was determined by measuring optical density (OD595) using a BioTek Epoch 
microplate spectrophotometer.  Readings were compared to a standard curve generated with 
sodium nitrite (Sigma).  
Results:  To demonstrate the presence and bioactivity of IL4 on H6N2 virions, HD11 
macrophages were incubated with H6N2 or H6N2-IL4.  Both NA and HA-anchored IL4 
molecules were tested for their ability to activate NO production in chicken macrophages.  NO 
levels in wells incubated with H6N2 were similar to background.  125-1000HAU/well of H6N2-
NA-IL4 were able to induce NO production to levels similar to those produced by 500ng of IL4.  
H6N2-IL4-HA was only able to induce high levels of NO production at 1000HAU/well.  These  
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Figure 7.  Bioassay for IL4 activity.  Dilutions of recombinant IL4 (white bars), wild type H6N2 
(light gray bars), H6N2-NA-IL4 (dark gray bars) and H6N2-IL4-HA were incubated with HD11 
chicken macrophages.  IL4 activity was measured by the induction of NO production in the 
HD11 cells, a sign of macrophage activation.  NO levels were measured using its stable 
metabolite, nitrite, with the Griess assay.  Samples were tested in triplicate and SEM was 
calculated (Representative assay).    
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results confirm the presence and activity of IL4 on H6N2 virions.  H6N2-NA-IL4 was selected 
for use in in vivo studies as it was bioactive across a wide range of doses. 
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Chapter 3 
Vaccination Studies in Chicks 
Materials and Methods:  All chicks used in vaccination studies were ISA Brown pullet 
egg layers purchased as day old chicks locally (Townline Farms, Zeeland, MI) and maintained in 
Division of Laboratory Animal Resources (DLAR) facilities at Wayne State University in 
accordance with institutional protocols.  In the preliminary vaccination trial 72 ISA Brown 
female chicks were divided into 8 experimental groups: saline vaccination control, no virus 
challenge (n=6), saline vaccination control with virus challenge (n=6), subcutaneous vaccination 
with H6N2 (n=12), H6N2-IL2 (n=12), H6N2-GMCSF (n=6) followed by live virus challenge, 
intranasal vaccination with H6N2 (n=12), H6N2-IL2 (n=12), H6N2-GMCSF (n=6) followed by 
live virus challenge.  21-day-old chickens were vaccinated subcutaneously at the base of the 
neck or intranasally with the inactivated A/Chick/California/2000-3 (H6N2) vaccines described 
above.  Vaccines contained 970 hemmaglutinating units (HAU) (approximately 8ug total viral 
protein) of virus resuspended in 100µl PBS.  10 days following the primary vaccination, 
chickens were challenged intranasally with 5X10
6
 TCID50 resuspended in 100µl PBS.  3 days 
following challenge oropharyngeal and cloacal swabs were collected and resuspended in viral 
transport medium (tissue culture medium 199 containing 0.5% BSA, penicillin (2X10
6
 U/liter), 
streptomycin 200 mg/liter, polymyxin B (2X10
6
 U/liter), gentamicin (250 mg/liter), nystatin 
(0.5X10
6
 U/liter), ofloxacin HCI (60 mg/liter), and sulfamethoxazole (0.2 g/liter)).  5 days post-
challenge serum was collected and the chicks were sacrificed. 
In the second vaccination trial a total of 91 chickens were used for immunization studies 
and divided into 10 experimental groups: saline control vaccination, no virus challenge (n=8), 
subcutaneous vaccination with saline control (n=9), H6N2 (n=10), H6N2-IL2 (n=9), H6N2-IL4 
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(n=9), H6N2-p29x6 (n=11), H6N2-GMCSF (n=10) followed by virus challenge, intranasal 
vaccination with H6N2 (n=10), H6N2-p29x6 (n=9) and H6N2-IL4 (n=6) followed by virus 
challenge.  Briefly, 3-week-old chickens were vaccinated subcutaneously at the base of the neck 
or intranasally with the inactivated A/Chick/California/2000-3 (H6N2) vaccines described above.  
Vaccines contained 2000 hemmaglutinating units (HAU) of virus resuspended in 100µl PBS.  
Immunized chickens were boosted 21 days later with the same dose of vaccine delivered by the 
same route.  2 weeks following the booster vaccination, chickens were challenged intranasally 
with 5X10
6
 TCID50 resuspended in 100µl PBS.  Serum was collected from each chicken 2 weeks 
following each vaccination and 1 week post-challenge. Oropharyngeal swabs were collected in 
1ml PBS 3 days post-challenge, stored at -80 C, and thawed only once for RNA extraction. 
Protective antibody assays:  Hemagglutination inhibition (HAI) responses were 
measured.  Sera were treated with receptor-destroying enzyme (RDE) (Cholera Filtrate; Sigma-
Aldrich) as described previously to remove non-specific inhibitors of hemagglutination (331, 
332).  Lyophillized RDE was reconstituted with 5ml sterile distilled water and diluted to 100ml 
with calcium saline, pH 7.2m aliquoted and stored at -20C.  RDE was added to each serum 
sample at a 4:1 ratio (0.2 ml RDE + 0.05ml serum) and incubated overnight at 37C.  Following 
the overnight incubation 5 volumes of 1.5% sodium citrate (0.25 ml) were added to each sample 
and incubated at 56C for 30 min to inactivate remaining RDE giving a starting serum dilution of 
1:10.  
Alternatively, if RDE treatment failed to sufficiently remove non-specific inhibitors, sera 
were treated with trypsin, heat and periodate as described elsewhere (333).  20µl of serum were 
combined with 10µl of 8 mg/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated 
trypsin (Sigma) in 0.1M phosphate buffer (pH 8.2) and incubated at 56°C for 30 min.  After 
68 
 
 
 
samples cooled to room temperature, 30µl 0.011M periodic acid (Sigma) were added, and the 
mixture was incubated for 15 min. 30µl of 1% glycerol saline was added, and the mixture was 
incubated at room temperature for 15 min.  Lastly, 2 volumes of phosphate-buffered saline were 
added to give a 1:10 dilution of the initial sample. 
HAI assays were performed by standard protocols (331).  Briefly, 25μl of wild-type 
H6N2 in PBS with an HA titer of 8 HA units/50µl was mixed with 25μl of twofold dilutions of 
each RDE-treated serum in V-bottomed 96-well plates. After 30 min of incubation at room 
temperature, 50μl of 0.5% chicken red blood cells were added to the mixtures. The plates were 
incubated at room temperature until red blood cells in non-virus-containing control wells settled. 
The HAI titer was calculated as the reciprocal of the last dilution of antiserum that completely 
inhibited hemagglutination. 
Influenza virus neutralization assays were also used.  MDCK cells were grown to 
confluence in 96 well flat bottom tissue culture plates.  Twofold serial dilutions of sera in viral 
growth medium were combined with 100 TCID50 H6N2, added to MDCK cells and incubated for 
2hrs.  The virus-antibody mixture was removed, plates were washed and fresh viral growth 
medium was added.  After 3 days, cells were observed for cytopathic effect.    
Titration of virus in swab samples:  MDCK cells were plated at 2X10
4
 cells per well in 
a 96 well flat bottom tissue culture plate.  Tracheal and cloacal swab supernatants were diluted 
1/25, 125, 625, 3125, 15625 and 78,125 in PBS with Ca
2+
 and Mg
2+
 and penicillin, streptomycin, 
fungizone and ciprofloxacin and added to washed MDCK cells.  Plates were incubated for 1hr at 
37C then rinsed and incubated with DMEM, penicillin, streptomycin and TPCK trypsin (2ug/ml) 
for 3 days at 37C. 
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RNA extraction and quantitative, real-time reverse-transcriptase polymerase chain 
reaction (RT-PCR):  Viral particles from oropharyngeal swabs were pelleted by 
ultracentrifugation in an SW55 Ti rotor (Sorvall) at 30,000 rpm (~85,300 x g) for 1hr at 4C.  
Viral RNA was prepared from lysates of the pelleted virus using the RealTime ready Cell Lysis 
Kit (Roche Inc.).  Lysates were treated with RNAse inhibitor according to the manufacturer’s 
instructions.  The Transcriptor Universal cDNA Master (Roche Inc.) was used to generate cDNA 
in a 20µl reaction mixture containing the following reagents: 12.5µl PCR grade water, 4µl 
reaction buffer, 1µl reverse transcriptase, 0.5µl thermolabile DNAse and 2µl viral RNA lysate.  
Reactions were performed in a Mastercycle pro thermal cycler (Eppendorf) with the following 
cycling conditions: primer annealing and DNAse degradation 10min at 29C, reverse transcription 
10min at 55C and denaturation 5min at 85C. 
Quantitative real-time PCR was carried out using the Roche FastStart Universal Probe 
Master (ROX) kit.  Reaction mixtures contained 5µl cDNA template, 25µl Roche FastStart 
Universal Probe Master Mix, 0.5µl FAM-labeled hydrolysis probe, 0.5µl forward primer, 0.5µl 
reverse primer and 18.5µl PCR-grade water.  Primer and probe sequences for influenza 
A/Chick/California/2000-3 (H6N2) M1 matrix protein were: forward primer 5’-
CGCCACATGTGAGCAGATT-3’, reverse primer 5’-ATTGTCACCATTTGCCTGTG-3’ and 
FAM-490 labeled Roche Universal Probe #159, 5’-CCAGCATC-3’.  Reactions were performed 
using a BioRad iCycler with the following cycling conditions:  1 cycle 50C for 2min, 1 cycle 
95C for 10min, 45 cycles of 95C 15sec, 60C 1min.  A melting curve was performed at the end of 
the experiment.  DNA was quantitated by the levels of hydrolyzed FAM-490. 
Statistical Analysis:  To determine whether seroconversion rates and viral clearance 
rates among the groups were significantly different from each other, Fisher’s two sided exact test 
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was performed and a value of p<0.05 was considered significant.  To determine whether HAI 
titers among the groups of chickens were significantly different from each other, analysis of 
variance (ANOVA) and Bonferoni’s Multiple Comparison Test (Prism, Graphpad) were 
performed and a value of p<0.05 was considered significant. 
Results: 
Preliminary Vaccination Trial:  This preliminary vaccination study was undertaken to 
assess the ability of heat-inactivated H6N2 avian influenza vaccines bearing GMCSF or IL2 
delivered subcutaneously or intranasally to strengthen immune responses to influenza in 
chickens.  To achieve this, 21 day old ISA Brown Pullet egg layers were vaccinated with H6N2, 
H6N2-IL2 or H6N2-GMCSF.  10 days after vaccination, chicks were challenged with live 
H6N2.  3 days after viral challenge, tracheal and cloacal swabs were taken to test for viral 
replication.  5 days after challenge, sera was collected to analyze antibody titers.  Chicks with 
HAI titer of 80 or higher after challenge were considered to be seroconverted and highly reactive 
to the challenge virus (Fig. 8).  None of the chicks mock-vaccinated with saline achieved 
seroconversion.  1/12 chicks vaccinated with H6N2 subcutaneously seroconverted.  6/12 chicks 
vaccinated with H6N2-IL2 subcutaneously, an increase over H6N2 alone (p=0.06) and a 
significant increase over mock vaccination (p<0.05).  4/6 chicks vaccinated with H6N2-GMCSF 
seroconverted, a significant increase over both mock vaccination and H6N2 (p<0.05).  After 
intranasal vaccination 1/12 chicks vaccinated with H6N2 and 0/12 chicks vaccinated with H6N2-
IL2 seroconverted.   6/12 chicks vaccinated intranasally with H6N2-GMCSF seroconverted, a 
moderate increase (p=0.08) compared to H6N2 delivered intranasally.  Titration of virus 
recovered from tracheal and cloacal swabs on MDCK cells was attempted however, results were 
unreliable due to a non-specific cytopathic effect unrelated to influenza infection. 
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Figure 8.  Seroconversion levels following vaccination and viral challenge.  Serum was 
collected 5 days after challenge and analyzed by HAI assay.  Chicks with GMTs of 80 or above 
were considered to be highly reactive and seroconverted. (* = p<0.05 compared to saline,  
x = p<0.05 compared to H6N2 subcutaneous, # = p=0.06, ^ = p=0.08) 
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These results indicated that adjuvanting subcutaneously delivered influenza vaccines with 
membrane-bound IL2 or GMCSF could increase antibody production in response to live viral 
challenge compared to vaccination with inactivated vaccine alone.  The data also indicated that 
adjuvanting intranasal influenza vaccines with membrane-bound GMCSF may moderately 
strengthen antibody responses while IL2 fails to do so. 
In vivo testing of H6N2 vaccine constructs:  A second vaccination trial was conducted 
with modifications from the preliminary study to further analyze H6N2-IL2 and H6N2-GMCSF 
and to test H6N2-IL4 and H6N2-p29x6.  All four constructs plus wild type H6N2 were tested as 
subcutaneous vaccinations.  Due to capacity and animal number limitations and failure of 
intranasal vaccination with H6N2-IL2 and H6N2-GMCSF to significantly improve 
seroconversion rates in the preliminary study, only wild type H6N2, H6N2-IL4 and H6N2-p29x6 
were tested intranasally.  Additional design changes include the use of a higher vaccine dose 
(2000HAU vs. 970HAU), the addition of a booster vaccination, serum collection after each 
vaccination and a longer time period between vaccination and challenge.  Others determined that 
RT-PCR could be used to reliably test oropharyngeal swabs for viral presence at its peak 
replication titers 3 days after challenge (217, 334).  This technique was utilized instead of viral 
titration of swab material in MDCK cells to eliminate the contamination issues seen in the 
preliminary study.  Furthermore, an HAI titer of 40 was considered to be positive for 
seroconversion, a standard more in line with USDA and WHO recommendations. 
 Chicks were vaccinated 21 days after hatching.  At day 35 (14 days after vaccination) 
sera were collected to measure antibody response to the primary vaccination and the booster 
vaccine was administered.  On day 49 sera were collected to measure antibody response to the 
booster vaccine and chicks were challenged with live H6N2.  On day 52, oropharyngeal swabs 
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were collected to test for viral replication (or clearance).  On day 56 sera were collected to 
analyze post-challenge antibody titers. 
 Serum Antibody Response to Vaccination:  After primary vaccination, average 
antibody titers determined by HAI were similar for unvaccinated controls and all subgroups of 
vaccinated chicks (Fig. 9).  A minimal number of chicks had HAI titers equal to or above the 
seroconversion level of 40 GMT (Fig. 10).  An influenza virus neutralization assay was also used 
after primary vaccination.  Chicks were considered to have increased protection if a 1/40 dilution 
of serum could neutralize 100 TCID50 H6N2.  In comparison to saline vaccinated chicks, chicks 
vaccinated with H6N2-IL4 (p<0.005), H6N2-p29x6 (p<0.00005) and H6N2-GMCSF (p<0.0005) 
subcutaneously and H6N2-p29x6 intranasally (p<0.05) had increased protection (Fig. 11).  In 
comparison to chicks vaccinated with H6N2 subcutaneously, those vaccinated with H6N2-
GMCSF (p<0.05) and H6N2-p29x6 (p<0.0005) subcutaneously had increased protection. 
Following booster vaccination groups vaccinated with H6N2-p29x6 and H6N2-GMCSF 
subcutaneously and H6N2-IL4 and H6N2-p29x6 intranasally averaged HAI titers greater than 40 
(Fig. 12).  In comparison to saline vaccinated chicks, chicks vaccinated with H6N2-p29x6 
(p<0.05) and H6N2-GMCSF (p<0.0005) subcutaneously and H6N2-p29x6 intranasally 
(p<0.0005) had significantly elevated antibody titers as measured by HAI.  Furthermore, in 
comparison to chicks vaccinated with H6N2 subcutaneously, those vaccinated with H6N2-
GMCSF (p<0.005) subcutaneously and H6N2-p29x6 intranasally (p<0.005) had significantly 
higher antibody titers.  Chicks vaccinated with H6N2-IL4 (p<0.05), H6N2-p29x6 (p<0.0005) 
and H6N2-GMCSF (p<0.0005) subcutaneously and H6N2 (p<0.05), H6N2-IL4 (p<0.05) and 
H6N2-p29x6 (p<0.0005) intranasally had significantly increased rates of seroconversion than 
those receiving saline (Fig. 13).  In comparison to chicks vaccinated with H6N2 subcutaneously,  
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Figure 9.  Average GMT following vaccination with 2000HAU at 21 days of age.  Serum was 
collected 14 days after vaccination and titers were determined by HAI assay.  HAI titers of 40 or 
greater were considered to be seroprotective. 
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Figure 10.  Percentage of chicks per group considered to have seroprotective titers as determined 
by HAI assay following primary vaccination. 
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Figure 11.  Percentage of chicks per group considered to have increased protective titers as 
determined by influenza virus neutralization assay following primary vaccination.  (* = p<0.05, 
** = p<0.005, *** = p<0.0005, **** = p<0.00005 compared to saline vaccinated chicks, # = 
p<0.05, ### = p<0.0005 compared to H6N2 subcutaneous vaccinated chicks) 
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Figure 12.  Average GMT following booster vaccination with 2000HAU at 35 days of age.  
Serum was collected 14 days after booster vaccination and titers were determined by HAI assay.  
HAI titers of 40 or greater were considered to be seroprotective.  (* = p<0.05, *** = p<0.0005 
compared to saline, ## = p < 0.005 compared to WT-H6N2 subcutaneous vaccinated chicks) 
 
A
v
e
r
a
g
e
 T
it
e
r

 S
E
M
S
a
li
n
e
H
6
N
2
H
6
N
2
-I
L
2
H
6
N
2
-I
L
4
H
6
N
2
-p
2
9
H
6
N
2
-G
M
C
S
F
H
6
N
2
H
6
N
2
-I
L
4
H
6
N
2
-p
2
9
0
1 0
2 0
3 0
5 0
6 0
7 0
8 0
40
*
# #
***
# #
***
S u b c u ta n e o u s  V a c c in a t io n In tr a n a s a l V a c c in a tio n
78 
 
 
 
 
Figure 13.  Percentage of chicks per group considered to have seroprotective titers as determined 
by HAI assay following booster vaccination.  (* = p<0.05, *** = p<0.0005 compared to saline,  
x = p<0.05 compared to H6N2 subcutaneous, ^ = p<0.05 H6N2 intranasal vaccinated chicks) 
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those vaccinated subcutaneously with H6N2-p29x6 (p<0.05) and H6N2-GMCSF (p<0.05) and 
H6N2-p29x6 (p<0.05) had significantly higher seroconversion rates.  Additionally, intranasal 
vaccination with H6N2-p29x6 resulted in a significantly higher seroconversion rate (p<0.05) 
than intranasal vaccination with H6N2. 
 Following challenge with live H6N2 all groups with the exception of saline controls had 
average HAI titers over 40 and at least 90% seroconversion (Figs. 14 & 15). 
 These results demonstrate that inactivated H6N2 vaccines with membrane-bound p29x6 
intranasally and subcutaneously enhances antibody titers and seroconversion compared to 
standard inactivated H6N2.  Additionally, adjuvanting with membrane-bound GMCSF results in 
a subcutaneous vaccine that increases antibody titers and seroconversion of subcutaneous 
produced by subcutaneous vaccination.  
Viral Shedding Following Vaccination and Challenge:  To assess the ability of the 
vaccine constructs to eliminate viral replication and shedding, oropharyngeal swabs were 
collected three days after challenge and tested for presence of H6N2 by RT-PCR.  On average, 
chicks that were positive for virus had HAI titers of 21 while those that were negative averaged 
an HAI titer of 45 (Fig. 16).  All saline vaccinated chicks challenged with live H6N2 were 
positive for H6N2 (Fig. 17).  Each vaccinated group exhibited a significantly reduced shedding 
in comparison to saline treated chicks (Fig. 17).  All chicks vaccinated with H6N2-p29X6 
subcutaneously and H6N2 and H6N2-p29x6 intranasally completely eliminated viral shedding, a 
significant improvement over vaccination with subcutaneous H6N2 alone (p<0.05).  
Interestingly, H6N2 was more effective in eliminating viral shedding when delivered 
intranasally.  These results indicate that p29x6 is an effective adjuvant for the reduction of viral 
shedding when delivered by either a subcutaneous or mucosal route.    
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Figure 14.  Average GMT following challenge with 5X10
6
 TCID50 at 49 days of age.  Serum 
was collected 7 days after challenge and titers were determined by HAI assay.  HAI titers of 40 
or greater were considered to be seroprotective.  (** = p<0.005 compared to saline, # = p < 0.05 
compared to WT-H6N2 subcutaneous vaccinated chicks).  Note: all chicks, including the saline 
control group, were challenged with live virus.  
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Figure 15.  Percentage of chicks per group considered to have seroprotective titers as determined 
by HAI assay following live virus challenge.  (* = p<0.05, ** = p<0.005 compared to saline 
vaccinated chicks).  Note: all chicks, including the saline control group, were challenged with 
live virus. 
 
 
 
 
 
  
P
e
r
c
e
n
t 
S
e
r
o
c
o
n
v
e
r
te
d
G
M
T

 4
0
S
a
li
n
e
H
6
N
2
H
6
N
2
-I
L
2
H
6
N
2
-I
L
4
H
6
N
2
-p
2
9
H
6
N
2
-G
M
C
S
F
H
6
N
2
H
6
N
2
-I
L
4
H
6
N
2
-p
2
9
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0 *
(n  =  1 0 )
*
(n  =  9 )
*
(n  =  9 )
*
(n  =  9 )
* *
(n  =  1 1 )
*
(n  =  1 0 )
*
(n  =  6 )
(n  =  9 )
*
(n  =  1 0 )
S u b c u ta n e o u s  V a c c in a t io n In tr a n a s a l V a c c in a tio n
82 
 
 
 
 
Figure 16.  HAI titers following booster vaccination of chicks negative or positive for H6N2 
three days following challenge.  Oropharyngeal swabs were collected 3 days after challenge and 
tested for viral presence by RT-PCR. 
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Figure 17.  Percentage of birds testing positive for H6N2 by RT-PCR three days after challenge.  
(* = p<0.05, ** = p<0.005, *** = p <0.0005, **** = p <0000.5 compared to challenged birds 
vaccinated with saline, x = p<0.05 compared to WT-H6N2 subcutaneous vaccination) 
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 Morbidity and Mortality:  H6N2 typically results in mild or inapparent illness.  All 
chicks were monitored for signs of illness, discomfort and weight loss.  As expected, no chicks 
displayed signs of illness and all continued to gain weight after viral challenge (Fig. 18). 
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Figure 18.  Weights of chicks in grams at vaccination (day 21), booster vaccination (day 35), 
live virus challenge (day 49), peak replication (day 52) and sacrifice (day 56). 
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Chapter 4 
General Conclusions 
 Avian influenza viruses are a threat to global human and animal health.  This danger has 
been exemplified by the multi-continent spread of highly pathogenic H5N1 and infections in 
both bird and human populations.  The development of improved vaccines is crucial for control 
of influenza in poultry and for pandemic prevention and response in humans.   
This study examined the efficacy of inactivated whole-virus avian influenza vaccines 
bearing four membrane-bound immunomodulators, produced in a mammalian cell culture-based 
system and tested in chickens.  It was demonstrated previously that avian GMCSF and IL2 could 
be incorporated into filamentous and spherical influenza virions.  This prior study found two 
doses of an inactivated vaccine consisting of filamentous human influenza virus bearing 
membrane-bound avian IL2 elicited stronger antibody responses than an unadjuvanted vaccine in 
chickens (215).  This system was also successfully tested in a mouse model with murine IL2 and 
IL4 (216).  This study builds upon these previous results by examining the effects of membrane-
bound GMCSF, C3d, IL2 and IL4 on antibody response and viral clearance using avian influenza 
vaccine in an avian model.  This study found that incorporation of membrane-bound avian 
GMCSF and C3d adjuvants into inactivated whole-virus avian influenza vaccines resulted in 
significantly enhanced antibody responses and significantly increased viral clearance when 
delivered subcutaneously (GMCSF and C3d) and intranasally (C3d) in comparison to an 
inactivated whole-virus vaccine without adjuvant.   
A drawback of classic inactivated vaccines is the failure to effectively stimulate innate 
immune responses and lack of efficient uptake by antigen-presenting cells.  The two most 
successful immunomodulators used in the study, C3d and GMCSF, both act on antigen 
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presenting cells.  GMCSF stimulates the growth and activation of macrophages and dendritic 
cells and C3d links the innate and adaptive immune systems and increases uptake by follicular 
dendritic cells.  The enhanced immune responses seen when C3d and GMCSF were incorporated 
into vaccine particles suggest that stimulating the growth and activation of antigen presenting 
cells and enhancing antigen uptake is key for improving inactivated vaccines.  An additional 
reason to suspect that these immunomodulators act on APC’s is that they are attached to killed 
influenza particles, which are not expected to persist for extended periods in the chickens.  
Consequently, it is suspected that virus particle interaction with APC’s could be influenced by 
immunomodulators affecting APC’s.  However, it is also possible that C3d on the virus particles 
interacts with naïve or cross-reactive B cells of low affinity for influenza viral antigens. 
In this study, IL4 and IL2 adjuvants were not able to significantly enhance immune 
responses as GMCSF and C3d did.  IL4 moderately boosted antibody titers and seroconversion 
rates and increased viral clearance in subcutaneous vaccinations, however these results did not 
achieve statistical significance.  These results did not match those of Herbert et al., which 
indicated that IL4 was a stronger adjuvant than GMCSF (216).  This suggests differences in 
activity and potency of murine and avian membrane-bound IL4.  Other possible explanations are 
that IL4 dosing must be refined in this system or that efficacy of IL4 adjuvantation may vary 
between influenza strains. 
The failure of IL2 as an adjuvant in the subcutaneously delivered vaccine was surprising 
following the results from Yang et al. (215).  Yang et al. found a significant increase in antibody 
titers in chicks following two doses of inactivated filamentous influenza bearing avian IL2.  With 
the exception of the induction of post-challenge antibody titers, IL2 was a weak or completely 
ineffective adjuvant in our study.  It should be noted that IL2 also boosted antibody responses 
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following challenge in our preliminary vaccination study however antibody levels were not 
tested following vaccination and prior to challenge.  It is possible that the filamentous H3N2 
A/Udorn/72 used in Yang et al. presents IL2 more efficiently than the spherical H6N2 used in 
this study.  Testing of membrane-bound IL2 in other spherical influenza viruses should be 
undertaken.  Additionally, dosage should be examined.  Yang et al. used a lower dose of virus 
(and in turn IL2).  As discussed above, high doses of certain cytokines can be inhibitory due to 
the induction of regulatory cells.  A broad range of vaccine doses and IL2 levels should be 
examined to determine if an optimal, stimulatory dose can be found.  Furthermore, IL2 and IL4 
do not actively facilitate the uptake of antigen, a factor that may hinder their usefulness as 
solitary adjuvants.  Future studies using this system should investigate combinations of 
adjuvants, particularly ones that stimulate antigen uptake in conjunction with those that act on T 
cells and B cells.  For example, one might consider the use of APC immunomodulators in a 
primary vaccination followed by T and/or B cell immunomodulators in a booster vaccination.    
An effective mucosal influenza vaccine would offer advantages in both agricultural and 
human practice.  For poultry, this would allow for mass administration by aerosol reducing 
handling and labor costs.  For humans it would have the potential to increase compliance rates in 
needlephobic patients.  For both groups, a mucosal vaccination offers the potential for improved 
mucosal immune responses and neutralization of virus at the infection site.  An important finding 
of this study was that C3d was highly effective as an adjuvant in intranasal vaccination with 
inactivated influenza virus.  Each chick receiving H6N2-C3d via the intranasal route 
seroconverted and cleared the challenge virus and as a group, average antibody titers were 
significantly higher than inactivated virus without adjuvant delivered by subcutaneous and 
intranasal routes.  These results indicate that C3d should be pursued further as a mucosal 
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adjuvant.  Another interesting finding was that intranasal vaccination with inactivated virus 
resulted in a moderate (but not statistically significant) increase in antibody titers and a 
significant increase in viral clearance when delivered intranasally compared to subcutaneously.  
This suggests that even if manufacturers choose not to pursue adjuvantation, further study of 
inactivated intranasal influenza vaccines is warranted. 
The standard egg-based influenza vaccine propagation system has many drawbacks, 
particularly long production times and capacity limitations.  A key feature of this study is the 
utilization of a mammalian cell culture line for production of both virions and adjuvants.   
MDCK cells were successfully transfected with membrane-bound immunomodulators and 
virions derived from these cells were successfully used in a vaccine model.  Membrane-bound 
immunomodulators should next be incorporated into suspension MDCK cell lines and MDCK 
cells modified to grow in serum-free medium to assess scalability and mass production. 
While this study further validated the membrane-bound immunomodulator adjuvant 
model in influenza, in addition to the aforementioned suggestions, steps need to be taken before 
it can be approved for use on a wide scale in poultry.  First, combinations of immunomodulators 
should be tested.  Finding the right mix of these adjuvants could lead to even more effective 
vaccines.  Second, this model must be tested using high pathogenicity AI viruses such as H5N1, 
H7N7 and H9N2 in BSL3 facilities before it can be deployed for widespread use.  Third, studies 
should be undertaken to determine how much of each immunomodulator is expressed on the 
surface of each virion.  Protocols will have to be standardized to produce vaccine particles 
bearing a consistent amount of adjuvant to appease regulatory agencies.  Furthermore, it needs to 
be determined how the expression of HA or NA anchored immunomodulators impacts the 
quantity of HA or NA antigens on a virion.  This is particularly important for the HA anchored 
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constructs as a significant drop in HA could severely reduce the immunogenicity of the vaccine.  
Finally, significant clinical and safety testing would need to be completed before consideration 
for use as a human vaccine. 
In conclusion C3d and GMCSF are highly effective immunomodulatory adjuvants when 
tethered to the surface of influenza virions.  These adjuvants and the cell culture-based 
production system offer to significantly enhance current influenza vaccines and have the 
potential for widespread use in the control of avian influenza. 
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Inactivated viral vaccines often generate suboptimal immune responses.  Adjuvants are 
incorporated into vaccines to increase their immunogenicity, however currently available 
adjuvants have shortcomings which have limited their use in human and veterinary medicine.  
This necessitates the development of new adjuvants and delivery systems.  Cytokines have been 
extensively tested as adjuvants in vaccines but challenges such as diffusion from antigen, short 
half-lives and production costs have been encountered.  To address this, we developed a 
technology that efficiently produces inactivated, whole-virus influenza vaccine bearing 
membrane-bound cytokines.  Tethering the cytokine to the antigen of interest keeps the 
immunomodulator in close contact with the antigen ensuring that immune cells recruited or 
activated by the adjuvant react with the antigen as well.  Influenza can be used to test this model 
since its surface proteins HA and NA contain conserved signal sequences that direct these 
proteins to the infected cell surface where they are picked up by budding virions.  Plasmids 
containing cytokines fused to these signal sequences are transfected into MDCK cell lines and, 
upon expression, the fusion proteins are directed to the lipid islands on the cell membrane.  
When the cells are infected with influenza, new virus assembles at the lipid islands and 
incorporates the fusion proteins into the viral envelope.  Furthermore, this in vitro cell culture-
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based production system bypasses many of the current limitations found in the egg-based 
influenza vaccine production system. 
This model was tested in a chicken model using membrane-bound C3d, GMCSF, IL2 and 
IL4 as adjuvants.  GMCSF adjuvanted vaccines delivered subcutaneously and C3d adjuvanted 
vaccines delivered subcutaneously and intranasally resulted in significantly higher antibody titers 
than vaccines with inactivated virus alone.  Vaccination with C3d adjuvanted virions by either 
route completely eliminated viral shedding after challenge with live virus and the GMCSF 
vaccine reduced the number of birds shedding virus.  In conclusion, these data support our 
hypothesis that this technology improves the efficacy of killed influenza vaccines.  More studies 
seem warranted to test additional immjunomodulators, influenza strains and other enveloped 
viruses.  
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